<!doctype html><html><head><meta charset=utf-8><title>Vitamin D and Calcium report for IoM - not much change - updated 2014</title>
<link rel=stylesheet href="/css/main.css?v=1753298154"><link rel=stylesheet href="/css/pagination.css?v=1753298154"><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css><script src="/js/search-suggestions.js?v=1753298154"></script><script src="/js/search.js?v=1753298154"></script><script type=module>
        
        window.initPagefind = async function() {
            try {
                console.log('Loading Pagefind module...');
                window.pagefind = await import('/pagefind/pagefind.js');
                if (!window.pagefind) {
                    throw new Error('Failed to load Pagefind module - import returned empty result');
                }
                
                console.log('Initializing Pagefind...');
                const initResult = await window.pagefind.init();
                console.log('Pagefind loaded and initialized');
                
                
                if (window.searchInstance) {
                    console.log('Notifying Search instance of Pagefind initialization');
                    window.searchInstance.initializePagefind(window.pagefind);
                    console.log('Search instance successfully notified');
                } else {
                    console.warn('Search instance not found in global scope yet, but Pagefind is loaded');
                    
                }
            } catch (error) {
                console.error('CRITICAL ERROR: Failed to initialize Pagefind:', error);
                
                const errorDetails = error.stack || error.message || String(error);
                console.error('Error details:', errorDetails);
                
                
                const statusEl = document.querySelector('#search-status');
                const inputEl = document.querySelector('#search-input');
                
                if (statusEl) {
                    statusEl.textContent = 'Search unavailable: ' + error.message;
                    statusEl.style.display = 'block';
                    statusEl.style.color = 'red';
                }
                
                if (inputEl) {
                    inputEl.disabled = true;
                    inputEl.placeholder = 'Search unavailable';
                }
            }
        };
        
        
        window.pagefindInitialized = false;
        
        
        document.addEventListener('DOMContentLoaded', () => {
            console.log('DOM loaded, initializing Pagefind...');
            window.initPagefind();
        });
    </script></head><body><div class=top-nav><div class=home-icon><a href=/ title="Go to Home Page"><svg viewBox="0 0 576 512" width="28" height="28"><path d="M575.8 255.5c0 18-15 32.1-32 32.1h-32l.7 160.2c0 2.7-.2 5.4-.5 8.1V472c0 22.1-17.9 40-40 40H456c-1.1.0-2.2.0-3.3-.1-1.4.1-2.8.1-4.2.1H416 392c-22.1.0-40-17.9-40-40V448 384c0-17.7-14.3-32-32-32H256c-17.7.0-32 14.3-32 32v64 24c0 22.1-17.9 40-40 40H160 128.1c-1.5.0-3-.1-4.5-.2-1.2.1-2.4.2-3.6.2H104c-22.1.0-40-17.9-40-40V360c0-.9.0-1.9.1-2.8V287.6H32c-18 0-32-14-32-32.1.0-9 3-17 10-24L266.4 8c7-7 15-8 22-8s15 2 21 7L564.8 231.5c8 7 12 15 11 24z"/></svg></a></div><div class=search-container><div class=search-icon><i class="fas fa-search"></i></div><input type=text id=search-input placeholder=Search... disabled><div id=suggestions class=search-suggestions style=display:none></div><ul id=search-results style=display:none></ul><div id=search-results-panel class=search-results-panel><div class=results-header>Search Results</div><ul id=search-results-panel-list class=results-list></ul></div></div></div><div class=container><div class="content content-full-width" role=main><article><div class=scroll-nav-top><a href=javascript:void(0); id=scroll-to-bottom class=scroll-button aria-label="Scroll to bottom" onclick='return window.scrollTo({top:document.body.scrollHeight,behavior:"smooth"}),!1'><svg width="16" height="16" fill="currentcolor" viewBox="0 0 16 16"><path d="M8 4a.5.5.0 01.5.5v5.793l2.146-2.147a.5.5.0 01.708.708l-3 3a.5.5.0 01-.708.0l-3-3a.5.5.0 11.708-.708L7.5 10.293V4.5A.5.5.0 018 4z"/></svg>
<span>Scroll to Bottom</span></a></div><h1>Vitamin D and Calcium report for IoM - not much change - updated 2014</h1><time>May 4, 2016</time><div data-pagefind-body><h4 id=i-classfas-fa-file-pdf-stylemargin-right-03emia-hrefhttpsd378j1rmrlek7xcloudfrontnetattachmentspdfvitamin-d-calcium-report-pdfdownload-the-entire-pdf-from-vitamindwikia><i class="fas fa-file-pdf" style=margin-right:.3em></i><a href=https://d378j1rmrlek7x.cloudfront.net/attachments/pdf/vitamin-d-calcium-report-.pdf>Download the entire PDF from VitaminDWiki</a></h4><div class=border style="background-color:#ff9;padding:15px;margin:10px 0;border-radius:5px;width:600px"><ul><li><p><a href=/posts/vitamin-d-deficiency>Vitamin D Deficiency</a></p></li><li><p><a href=/posts/is-the-institute-of-medicine-report-on-calcium-and-vitamin-d-good-science style=color:red;text-decoration:underline title="This post/category does not exist yet: Is the Institute of Medicine Report on Calcium and Vitamin D Good Science - Jan 2011">Is the Institute of Medicine Report on Calcium and Vitamin D Good Science - Jan 2011</a></p></li><li><p><a href=/posts/wonder-about-conflict-of-interest-of-iom-panel-members style=color:red;text-decoration:underline title="This post/category does not exist yet: Wonder about conflict of interest of IoM panel members">Wonder about conflict of interest of IoM panel members</a></p></li></ul></div><h4 id=this-is-an-update-of-the-report-used-by-the-institute-of-medicine-in-2010>This is an update of the report used by the Institute of Medicine in 2010</h4><p><strong>Just introduction and Executive summary on this page</strong></p><!doctype html><html><head><meta charset=utf-8><meta name=generator content="‎ABBYY PDF Transformer+‎"><link rel=stylesheet href=vitamin-d-calcium-report-_files/vitamin-d-calcium-report-.css type=text/css></head><body><p><span class=font11 style=font-weight:700;font-style:italic;text-decoration:underline>Evidence Report/Technology Assessment</span></p><a name=caption1></a><h3><a name=bookmark0></a><span class=font3 style=font-weight:700>Number 217</span></h3><a name=caption2></a><h1><a name=bookmark1></a><span class=font5 style=font-weight:700>Vitamin D and Calcium: A Systematic Review of Health Outcomes (Update)</span></h1><p><span class=font8 style=font-weight:700>Prepared for:</span></p><p><span class=font8>Agency for Healthcare Research and Quality U.S. Department of Health and Human Services&nbsp;540 Gaither Road&nbsp;Rockville, MD 20850&nbsp;<a href=http://www.ahrq.gov>www.ahrq.gov</a></span></p><p><span class=font8 style=font-weight:700>Contract No. 290-2012-00006-I Prepared by:</span></p><p><span class=font8>Southern California Evidence-based Practice Center Santa Monica, CA</span></p><p><span class=font8 style=font-weight:700>Investigators:</span></p><p><span class=font8>Sydne J. Newberry, Ph.D.</span></p><p><span class=font8>Mei Chung, Ph.D., M.P.H Paul G. Shekelle, M.D., Ph.D.</span></p><p><span class=font8>Marika Suttorp Booth, M.S.</span></p><p><span class=font8>Jodi L. Liu, M.S.</span></p><p><span class=font8>Alicia Ruelaz Maher, M.D.</span></p><p><span class=font8>Aneesa Motala, B.A.</span></p><p><span class=font8>Mike Cui, M.P.H.</span></p><p><span class=font8>Tanja Perry, B.H.M.</span></p><p><span class=font8>Roberta Shanman, M.L.S.</span></p><p><span class=font8>Ethan M. Balk, M.D., M.P.H</span></p><p><span class=font8 style=font-weight:700>AHRQ Publication No. 14-E004-EF September 2014</span></p><p><span class=font8>This report is based on research conducted by the Southern California Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville,&nbsp;MD (Contract No. 290-2012-00006-I). The findings and conclusions in this document are those&nbsp;of the author(s), who are responsible for its contents; the findings and conclusions do not&nbsp;necessarily represent the views of AHRQ. Therefore, no statement in this report should be&nbsp;construed as an official position of AHRQ or of the U.S. Department of Health and Human&nbsp;Services.</span></p><p><span class=font8>The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed&nbsp;decisions and thereby improve the quality of health care services. This report is not intended to&nbsp;be a substitute for the application of clinical judgment. Anyone who makes decisions concerning&nbsp;the provision of clinical care should consider this report in the same way as any medical&nbsp;reference and in conjunction with all other pertinent information, i.e., in the context of available&nbsp;resources and circumstances presented by individual patients.</span></p><p><span class=font8>This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage&nbsp;policies. AHRQ or U.S. Department of Health and Human Services endorsement of such&nbsp;derivative products may not be stated or implied.</span></p><p><span class=font8>This report may periodically be assessed for the urgency to update. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the&nbsp;Effective Health Care Program Web site at <a href=http://www.effectivehealthcare.ahrq.gov>www.effectivehealthcare.ahrq.gov</a>. Search on the title&nbsp;of the report.</span></p><p><span class=font8>This document is in the public domain and may be used and reprinted without permission except those copyrighted materials that are clearly noted in the document. Further reproduction of those&nbsp;copyrighted materials is prohibited without the specific permission of copyright holders.</span></p><p><span class=font8>Persons using assistive technology may not be able to fully access information in this report. For assistance, contact <a href=mailto:EffectiveHealthCare@ahrq.hhs.gov>EffectiveHealthCare@ahrq.hhs.gov</a>.</span></p><p><span class=font8>None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.</span></p><p><span class=font8 style=font-weight:700>Suggested citation: </span><span class=font8>Newberry SJ, Chung M, Shekelle PG, Booth MS, Liu JL, Maher AR,</span></p><p><span class=font8>Motala A, Cui M, Perry T, Shanman R, Balk EM. Vitamin D and Calcium: A Systematic Review of Health Outcomes (Update). Evidence Report/Technology Assessment No. 217. (Prepared by&nbsp;the Southern California Evidence-based Practice Center under Contract No. 290-2012-00006-I.)&nbsp;AHRQ Publication No. 14-E004-EF. Rockville, MD: Agency for Healthcare Research and&nbsp;Quality. September 2014. <a href=http://www.effectivehealthcare.ahrq.gov/reports/final.cfm>www.effectivehealthcare.ahrq.gov/reports/final.cfm</a>.</span></p><h2><a name=bookmark2></a><span class=font4 style=font-weight:700>Preface</span></h2><p><span class=font8>The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of evidence reports and technology&nbsp;assessments to assist public- and private-sector organizations in their efforts to improve the&nbsp;quality of health care in the United States. The Office of Dietary Supplements/National Institutes&nbsp;of Health provided funding for this report.</span></p><p><span class=font8>The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions and new health care technologies and&nbsp;strategies. The EPCs systematically review the relevant scientific literature on topics assigned to&nbsp;them by AHRQ and conduct additional analyses when appropriate prior to developing their&nbsp;reports and assessments.</span></p><p><span class=font8>To bring the broadest range of experts into the development of evidence reports and health technology assessments, AHRQ encourages the EPCs to form partnerships and enter into&nbsp;collaborations with other medical and research organizations. The EPCs work with these partner&nbsp;organizations to ensure that the evidence reports and technology assessments they produce will&nbsp;become building blocks for health care quality improvement projects throughout the Nation. The&nbsp;reports undergo peer review and public comment prior to their release as a final report.</span></p><p><span class=font8>AHRQ expects that the EPC evidence reports and technology assessments will inform individual health plans, providers, and purchasers as well as the health care system as a whole by&nbsp;providing important information to help improve health care quality.</span></p><p><span class=font8>We welcome comments on this evidence report. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road,&nbsp;Rockville, MD 20850, or by email to <a href=mailto:epc@ahrq.hhs.gov>epc@ahrq.hhs.gov</a>.</span></p><div><p><span class=font8>Richard Kronick, Ph.D.</span></p><p><span class=font8>Director</span></p><p><span class=font8>Agency for Healthcare Research and Quality</span></p><p><span class=font8>Stephanie Chang, M.D., M.P.H.</span></p><p><span class=font8>Director</span></p><p><span class=font8>Evidence-based Practice Program Center for Evidence and Practice&nbsp;Improvement</span></p><p><span class=font8>Agency for Healthcare Research and Quality</span></p><p><span class=font8>Christine Taylor, Ph.D.</span></p><p><span class=font8>Scientific Consultant, Office of Dietary Supplements</span></p><p><span class=font8>National Institutes of Health</span></p><p><span class=font8>Paul M. Coates, Ph.D.</span></p><p><span class=font8>Director, Office of Dietary Supplements National Institutes of Health</span></p></div><br clear=all><div><p><span class=font8>Yen-pin Chiang, Ph.D.</span></p><p><span class=font8>Acting Deputy Director</span></p><p><span class=font8>Center for Evidence and Practice</span></p><p><span class=font8>Improvement</span></p><p><span class=font8>Agency for Healthcare Research and Quality</span></p><p><span class=font8>Aysegul Gozu, M.D., M.P.H.</span></p><p><span class=font8>Task Order Officer</span></p><p><span class=font8>Center for Evidence and Practice</span></p><p><span class=font8>Improvement</span></p><p><span class=font8>Agency for Healthcare Research and Quality</span></p><p><span class=font8>Elizabeth A. Yetley, Ph.D.</span></p><p><span class=font8>Senior Nutrition Research Scientist, Retired Office of Dietary Supplements&nbsp;National Institutes of Health</span></p></div><br clear=all><h2><a name=bookmark3></a><span class=font4 style=font-weight:700>Acknowledgments</span></h2><p><span class=font8>We would like to thank Sean Rubin and Patricia Smith for their administrative support for the updated report. Additionally, we would like to thank Nono Ayivi-Guedehoussou, Dan Han,&nbsp;and Adeyemi Okunogbe for their support in helping with extracting the results data.</span></p><div><h2><a name=bookmark4></a><span class=font4 style=font-weight:700>Technical Expert Panel</span></h2><p><span class=font8>Glenville Jones, Ph.D.</span></p><p><span class=font8>Professor, Biochemistry and Medicine Department of Biomedical & Molecular&nbsp;Sciences,</span></p><p><span class=font8>Queen’s University Kingston, Ontario, Canada&nbsp;Scientific Advisory Board&nbsp;Cytochroma Inc.</span></p><p><span class=font8>Markham, Ontario, Canada</span></p></div><br clear=all><div><p><span class=font8>Susan T. Mayne, Ph.D., F.A.C.E. Department Chair and C.-E.A. Winslow&nbsp;Professor</span></p><p><span class=font8>Chronic Disease Epidemiology Yale School of Public Health&nbsp;Associate Director for Population Sciences&nbsp;Research</span></p><p><span class=font8>Yale Cancer Center New Haven, CT</span></p><p><span class=font8>Clifford Rosen, M.D.</span></p><p><span class=font8>Senior Scientist</span></p><p><span class=font8>Maine Medical Center Research Institute Scarborough, ME</span></p><p><span class=font8>Director of Clinical and Translational Research</span></p><p><span class=font8>Maine Medical Center Portland, ME</span></p></div><br clear=all><div><h2><a name=bookmark5></a><span class=font4 style=font-weight:700>Peer Reviewers</span></h2><p><span class=font8>Patsy Brannon, Ph.D.</span></p><p><span class=font8>Professor, Division of Nutritional Sciences Cornell University&nbsp;Ithaca, NY</span></p><p><span class=font8>Kevin D. Cashman Professor of Food and Health&nbsp;School of Food & Nutritional Sciences&nbsp;University College Cork&nbsp;Cork, Ireland</span></p><p><span class=font8>J. Christopher Gallagher, M.D.</span></p><p><span class=font8>Professor of Endocrinology Director of Bone Metabolism Unit&nbsp;Creighton University&nbsp;Omaha, NE</span></p></div><br clear=all><div><p><span class=font8>Michael F. Holick, Ph.D., M.D.</span></p><p><span class=font8>Professor of Medicine, Physiology, and Biophysics</span></p><p><span class=font8>Boston University School of Medicine Boston, MA</span></p><p><span class=font8>Anne C. Looker, Ph.D.</span></p><p><span class=font8>National Center for Health Statistics Centers for Disease Control and Prevention&nbsp;Hyattsville, MD</span></p></div><br clear=all><h1><a name=bookmark6></a><span class=font5 style=font-weight:700>Vitamin D and Calcium: A Systematic Review of Health Outcomes (Update)</span></h1><h2><a name=bookmark7></a><span class=font4 style=font-weight:700>Structured Abstract</span></h2><p><span class=font8 style=font-weight:700>Background. </span><span class=font8>In 2009, the Institute of Medicine/Food and Nutrition Board constituted a Dietary Reference Intakes (DRI) committee to undertake a review of the evidence that had emerged&nbsp;(since the 1997 DRI report) on the relationship of vitamin D and calcium, both individually and&nbsp;combined, to a wide range of health outcomes, and potential revision of the DRI values for these&nbsp;nutrients. To support that review, several United States and Canadian Federal Government&nbsp;agencies commissioned a systematic review of the scientific literature for use during the&nbsp;deliberations by the committee. The intent was to support a transparent literature review process&nbsp;and provide a foundation for subsequent reviews of the nutrients. The committee used the&nbsp;resulting literature review in their revision of the DRIs.</span></p><p><span class=font8>In 2013, in preparation for a project the National Institutes of Health Office of Dietary Supplements (NIH/ODS) was undertaking related to evidence-based decisionmaking for vitamin&nbsp;D in primary care, based on the updated DRI report, the ODS and AHRQ requested an update to&nbsp;the 2009 systematic review to incorporate the findings of studies conducted since the 2009&nbsp;evidence review on the relationship between vitamin D alone or vitamin D plus calcium to&nbsp;selected health outcomes and to report on the methods used to assay vitamin D in the included&nbsp;trials.</span></p><p><span class=font8 style=font-weight:700>Purpose. </span><span class=font8>To systematically summarize the evidence on the relationship between vitamin D alone or in combination with calcium on selected health outcomes included in the earlier review:&nbsp;primarily those related to bone health, cardiovascular health, cancer, immune function,&nbsp;pregnancy, all-cause mortality, and vitamin D status; and to identify the vitamin D assay&nbsp;methods and procedures used for the interventional studies that aimed to assess the effect of&nbsp;vitamin D administration on serum 25(OH)D concentrations, and to stratify key outcomes by&nbsp;methods used to assay serum 25(OH)D concentrations.</span></p><p><span class=font8 style=font-weight:700>Data sources. </span><span class=font8>MEDLINE®; Cochrane Central; Cochrane Database of Systematic Reviews; and the Health Technology Assessments; search limited to English-language articles on humans.</span></p><p><span class=font8 style=font-weight:700>Study selection. </span><span class=font8>Primary interventional or prospective observational studies that reported outcomes of interest in human subjects in relation to vitamin D alone or in combination with&nbsp;calcium, as well as systematic reviews that met the inclusion and exclusion criteria.</span></p><p><span class=font8 style=font-weight:700>Data extraction. </span><span class=font8>A standardized protocol with predefined criteria was used to extract details on study design, interventions, outcomes, and study quality.</span></p><p><span class=font8 style=font-weight:700>Data synthesis. </span><span class=font8>We summarized 154 newly identified primary articles and two new systematic reviews that incorporated more than 93 additional primary articles. Available evidence focused&nbsp;mainly on bone health, cardiovascular diseases, or cancer outcomes. Findings were inconsistent&nbsp;across studies for bone health; breast, colorectal, and prostate cancer; cardiovascular disease and&nbsp;mortality; immune function; and pregnancy-related outcomes. Few studies assessed pancreatic&nbsp;cancer and birth outcomes. One new systematic review of observational studies found that&nbsp;circulating 25(OH)D was generally inversely associated with risk for cardiovascular disease.&nbsp;Methods used to assay serum 25(OH)D in studies reporting on key outcomes diverged widely.&nbsp;The current report also identified one new systematic review published since the original report&nbsp;that addressed whether a dose response relationship exists between dietary and supplemental&nbsp;vitamin D intake and serum 25(OH)D concentrations. The systematic review, based on 76 RCTs,&nbsp;reported widely varying increases in serum concentrations of 25(OH)D for similar doses of&nbsp;vitamin D, with a general increase in serum concentration with dietary intake. The RCTs&nbsp;identified for the current report found increases in serum 25(OH)D with supplementation;&nbsp;however, the findings varied by age group and health status of participants, baseline vitamin D&nbsp;status, dose, duration, and assay used to assess serum 25(OH)D.</span></p><p><span class=font8 style=font-weight:700>Limitations. </span><span class=font8>Studies on vitamin D and calcium were not specifically targeted at life stages (except for pregnant and postmenopausal women) specified for the determination of DRI and&nbsp;were often underpowered for their intended outcomes. Studies vary widely in methodological&nbsp;quality and in the assays used to measure vitamin D status.</span></p><p><span class=font8 style=font-weight:700>Conclusions. </span><span class=font8>In solid agreement with the findings of the original report, the majority of the findings concerning vitamin D, alone or in combination with calcium, on the health outcomes of&nbsp;interest were inconsistent. Associations observed in prospective cohort and nested case-control&nbsp;studies were inconsistent, or when consistent, were rarely supported by the results of randomized&nbsp;controlled trials. Clear dose-response relationships between intakes of vitamin D and health&nbsp;outcomes were rarely observed. Although a large number of new studies (and longer followups&nbsp;to older studies) were identified, particularly for cardiovascular outcomes, all-cause mortality,&nbsp;several types of cancer, and intermediate outcomes for bone health, no firm conclusions can be&nbsp;drawn. Studies identified for the current report suggest a possible U-shaped association between&nbsp;serum 25(OH)D concentrations and both all-cause mortality and hypertension and also suggest&nbsp;that the level of supplemental vitamin D and calcium administered in the Women’s Health&nbsp;Initiative Calcium-Vitamin D Trial are not associated with an increased risk for cardiovascular&nbsp;disease or cancer among postmenopausal women who are not taking additional supplemental&nbsp;vitamin D and calcium. Studies suggest the method used to assay 25(OH)D may influence the&nbsp;outcomes of dose-response assessments. Beyond these observations, it is difficult to make any&nbsp;substantive statements on the basis of the available evidence concerning the association of either&nbsp;serum 25(OH)D concentration, vitamin D supplementation, calcium intake, or the combination&nbsp;of both nutrients, with the various health outcomes because most of the findings were&nbsp;inconsistent.</span></p><h1><a name=bookmark8></a><span class=font5 style=font-weight:700>Contents</span></h1><p><span class=font8><a href=#bookmark9>Executive Summary................................................................................................................ES-1</a></span></p><p><span class=font8><a href=#bookmark10>Introduction...................................................................................................................................1</a></span></p><p><span class=font8><a href=#bookmark11>Background...............................................................................................................................1</a></span></p><p><span class=font8><a href=#bookmark12>Sources, Metabolism and Functions of Vitamin D...................................................................2</a></span></p><p><span class=font8><a href=#bookmark13>Sources, Metabolism, and Functions of Calcium.....................................................................5</a></span></p><p><span class=font8><a href=#bookmark14>Challenges for the DRI Committees.........................................................................................5</a></span></p><p><span class=font8><a href=#bookmark15>Key Questions Addressed in This Report.................................................................................7</a></span></p><p><span class=font8><a href=#bookmark16>Methods..........................................................................................................................................9</a></span></p><p><span class=font8><a href=#bookmark17>Overview...................................................................................................................................9</a></span></p><p><span class=font8><a href=#bookmark18>Sponsoring Federal Agencies.............................................................................................9</a></span></p><p><span class=font8><a href=#bookmark19>AHRQ Task Order Officer..................................................................................................9</a></span></p><p><span class=font8><a href=#bookmark4>Technical Expert Panel.......................................................................................................9</a></span></p><p><span class=font8><a href=#bookmark20>EPC Methodologists.........................................................................................................10</a></span></p><p><span class=font8><a href=#bookmark21>Development of the Analytic Framework and Refinement of Key Questions.......................10</a></span></p><p><span class=font8><a href=#bookmark22>Definitions...............................................................................................................................12</a></span></p><p><span class=font8><a href=#bookmark23>Vitamin D and Calcium Exposures...................................................................................12</a></span></p><p><span class=font8><a href=#bookmark24>Clinical Outcomes.............................................................................................................13</a></span></p><p><span class=font8><a href=#bookmark25>Indicators of Exposure (Nutrient Intake)..........................................................................13</a></span></p><p><span class=font8><a href=#bookmark26>Surrogate Outcomes..........................................................................................................13</a></span></p><p><span class=font8><a href=#bookmark27>Intermediate Outcomes.....................................................................................................13</a></span></p><p><span class=font8><a href=#bookmark28>Life Stages........................................................................................................................13</a></span></p><p><span class=font8><a href=#bookmark29>Key Questions.........................................................................................................................14</a></span></p><p><span class=font8><a href=#bookmark30>Literature Search Strategy.......................................................................................................15</a></span></p><p><span class=font8><a href=#bookmark31>Study Selection.......................................................................................................................16</a></span></p><p><span class=font8><a href=#bookmark32>Abstract Screening............................................................................................................16</a></span></p><p><span class=font8><a href=#bookmark33>Full-Text Article Eligibility Criteria.................................................................................16</a></span></p><p><span class=font8><a href=#bookmark34>Other Specific Eligibility Criteria.....................................................................................19</a></span></p><p><span class=font8><a href=#bookmark35>Data Extraction.................................................................................................................20</a></span></p><p><span class=font8><a href=#bookmark36>Data Analysis..........................................................................................................................21</a></span></p><p><span class=font8><a href=#bookmark37>MetaAnalysis..........................................................................................................................22</a></span></p><p><span class=font8><a href=#bookmark38>Grading of Studies Analyzed in This Evidence Report..........................................................22</a></span></p><p><span class=font8><a href=#bookmark39>Critical Appraisal and Grading of Primary Studies................................................................22</a></span></p><p><span class=font8><a href=#bookmark40>Grade A..............................................................................................................................23</a></span></p><p><span class=font8><a href=#bookmark41>Grade B..............................................................................................................................23</a></span></p><p><span class=font8><a href=#bookmark42>Grade C..............................................................................................................................23</a></span></p><p><span class=font8>Additional Considerations of Methodological Quality of Primary Studies for the</span></p><p><span class=font8><a href=#bookmark43>Purpose of DRI Decisionmaking......................................................................................24</a></span></p><p><span class=font8><a href=#bookmark44>Critical Appraisal of Systematic Reviews..............................................................................24</a></span></p><p><span class=font8><a href=#bookmark45>Reporting of the Evidence......................................................................................................25</a></span></p><p><span class=font8><a href=#bookmark46>Evidence Tables................................................................................................................25</a></span></p><p><span class=font8><a href=#bookmark47>Summary Tables...............................................................................................................25</a></span></p><p><span class=font8><a href=#bookmark48>Graphical Presentation of Dose-Response Relationship...................................................25</a></span></p><p><span class=font8><a href=#bookmark49>Grand Summary Tables (Evidence Map).........................................................................25</a></span></p><p><span class=font8><a href=#bookmark50>Units of Measurement.......................................................................................................26</a></span></p><p><span class=font8><a href=#bookmark51>Assay Method...................................................................................................................26</a></span></p><p><span class=font8><a href=#bookmark52>Sunlight Exposure.............................................................................................................26</a></span></p><p><span class=font8><a href=#bookmark53>Primary and Secondary Outcomes....................................................................................27</a></span></p><p><span class=font8><a href=#bookmark54>Study Quality....................................................................................................................27</a></span></p><p><span class=font8><a href=#bookmark55>Peer Review and Public Commentary....................................................................................27</a></span></p><p><span class=font8><a href=#bookmark56>Results..........................................................................................................................................28</a></span></p><p><span class=font8><a href=#bookmark57>Organization of the Results Section........................................................................................28</a></span></p><p><span class=font8><a href=#bookmark58>Literature Search Results........................................................................................................28</a></span></p><p><span class=font8><a href=#bookmark59>Vitamin D and Health Outcomes............................................................................................33</a></span></p><p><span class=font8><a href=#bookmark60>Vitamin D &nbsp;&nbsp;&nbsp;and Growth......................................................................................................33</a></span></p><p><span class=font8><a href=#bookmark61>Vitamin D &nbsp;&nbsp;&nbsp;and Cardiovascular Disease............................................................................48</a></span></p><p><span class=font8><a href=#bookmark62>Vitamin D &nbsp;&nbsp;&nbsp;and Body Weight............................................................................................89</a></span></p><p><span class=font8><a href=#bookmark63>Vitamin D &nbsp;&nbsp;&nbsp;and Cancer......................................................................................................93</a></span></p><p><span class=font8><a href=#bookmark64>Vitamin D &nbsp;&nbsp;&nbsp;and Immunologic Outcomes.........................................................................163</a></span></p><p><span class=font8><a href=#bookmark65>Vitamin D &nbsp;&nbsp;&nbsp;and Pregnancy-Related Outcomes................................................................187</a></span></p><p><span class=font8><a href=#bookmark66>Vitamin D &nbsp;&nbsp;&nbsp;and Clinical Outcomes of Bone Health........................................................199</a></span></p><p><span class=font8><a href=#bookmark67>Vitamin D &nbsp;&nbsp;&nbsp;and All-Cause Mortality...............................................................................224</a></span></p><p><span class=font8><a href=#bookmark68>Vitamin D &nbsp;&nbsp;&nbsp;and Hypertension and Blood Pressure..........................................................242</a></span></p><p><span class=font8><a href=#bookmark69>Vitamin D &nbsp;&nbsp;&nbsp;and Bone Mineral Density or Bone Mineral Content...................................260</a></span></p><p><span class=font8><a href=#bookmark70>Combined Vitamin D and Calcium and Health Outcomes...................................................273</a></span></p><p><span class=font8><a href=#bookmark71>Combined Vitamin D &nbsp;&nbsp;&nbsp;and Calcium and Growth.............................................................273</a></span></p><p><span class=font8><a href=#bookmark72>Combined Vitamin D &nbsp;&nbsp;&nbsp;and Calcium and Cardiovascular Disease...................................274</a></span></p><p><span class=font8><a href=#bookmark73>Combined Vitamin D &nbsp;&nbsp;&nbsp;and Calcium and Body Weight...................................................280</a></span></p><p><span class=font8><a href=#bookmark74>Combined Vitamin D &nbsp;&nbsp;&nbsp;and Calcium and Cancer.............................................................284</a></span></p><p><span class=font8><a href=#bookmark75>Combined Vitamin D &nbsp;&nbsp;&nbsp;and Calcium and Pregnancy-Related Outcomes.........................295</a></span></p><p><span class=font8><a href=#bookmark76>Combined Vitamin D &nbsp;&nbsp;&nbsp;and Calcium and Clinical Outcomes of Bone Health.................298</a></span></p><p><span class=font8><a href=#bookmark77>Combined Vitamin D &nbsp;&nbsp;&nbsp;and Calcium and All-Cause Mortality........................................306</a></span></p><p><span class=font8><a href=#bookmark78>Combined Vitamin D &nbsp;&nbsp;&nbsp;and Calcium and Hypertension and Blood Pressure...................310</a></span></p><p><span class=font8>Combined Vitamin D &nbsp;&nbsp;&nbsp;and Calcium and Bone Mineral Density or Bone Mineral</span></p><p><span class=font8><a href=#bookmark8>Content............................................................................................................................317</a></span></p><p><span class=font8>How Does Dietary Intake of Vitamin D From Fortified Foods and Vitamin D</span></p><p><span class=font8><a href=#bookmark79>Supplementation Affect Serum 25(OH)D Concentrations (Arrow 4)?................................328</a></span></p><p><span class=font8>RCTs on Dietary Intakes of Vitamin D From Fortified Foods and Serum 25(OH)D</span></p><p><span class=font8><a href=#bookmark80>Concentrations................................................................................................................328</a></span></p><p><span class=font8><a href=#bookmark81>RCTs on Vitamin D Supplementation and Serum 25(OH)D Concentrations................329</a></span></p><p><span class=font8><a href=#bookmark82>Stratification of Key Outcomes by Vitamin D Assay Method.............................................339</a></span></p><p><span class=font8><a href=#bookmark83>Outcomes for Tolerable Upper Intake Levels.......................................................................339</a></span></p><p><span class=font8><a href=#bookmark84>Renal Outcomes..............................................................................................................339</a></span></p><p><span class=font8><a href=#bookmark85>Adverse Events Reported in RCTs.................................................................................340</a></span></p><p><span class=font8><a href=#bookmark86>Discussion...................................................................................................................................346</a></span></p><p><span class=font8><a href=#bookmark87>Strengths of This Report.......................................................................................................347</a></span></p><p><span class=font8><a href=#bookmark88>DRI and the Literature on Vitamin D and Calcium..............................................................348</a></span></p><p><span class=font8><a href=#bookmark89>Limitations of Our Methodological Approach.....................................................................349</a></span></p><p><span class=font8><a href=#bookmark90>Comments on the Observational Studies..............................................................................350</a></span></p><p><span class=font8><a href=#bookmark91>Sources of Heterogeneity and Potential Biases....................................................................351</a></span></p><p><span class=font8><a href=#bookmark92>Vitamin D Intake and Response in Serum 25(OH)D Concentration..............................351</a></span></p><p><span class=font8><a href=#bookmark93>Considerations for Future DRI Committees.........................................................................352</a></span></p><p><span class=font8><a href=#bookmark94>References..................................................................................................................................353</a></span></p><p><span class=font8><a href=#bookmark95>Abbreviations............................................................................................................................371</a></span></p><p><span class=font8><a href=#bookmark96>Latitudes of Selected Cities......................................................................................................374</a></span></p><p><span class=font8>Tables</span></p><p><span class=font8><a href=#bookmark97>Table A. Findings of the original report compared with the current report............................ES-21</a></span></p><p><span class=font8>Table 1. Number of primary studies on vitamin D intake or concentration and specific health outcomes that could be applicable to certain life stages [updated for the current</span></p><p><span class=font8><a href=#bookmark98>report]............................................................................................................................................ 31</a></span></p><p><span class=font8>Table 2. Number of primary studies on calcium intake and specific health outcomes that</span></p><p><span class=font8><a href=#bookmark99>could be applicable to certain life stages [not updated in the current report]...............................32</a></span></p><p><span class=font8>Table 3. Number of primary studies on combined vitamin D and calcium intake and specific</span></p><p><span class=font8><a href=#bookmark100>health outcomes that are relevant to certain life stages [updated for the current report]..............33</a></span></p><p><span class=font8>Table 4. Vitamin D and growth outcomes: Characteristics of interventional studies (updated</span></p><p><span class=font8><a href=#bookmark101>from original report).....................................................................................................................38</a></span></p><p><span class=font8>Table 5. Vitamin D and growth outcomes: Characteristics of cohort studies (updated from</span></p><p><span class=font8><a href=#bookmark102>original report)..............................................................................................................................41</a></span></p><p><span class=font8><a href=#bookmark103>Table 6. Vitamin D and growth outcomes: Results of RCTs (updated from original report)......42</a></span></p><p><span class=font8>Table 7. Vitamin D and growth outcomes: Results of cohort studies (updated from original</span></p><p><span class=font8><a href=#bookmark104>report)............................................................................................................................................ 45</a></span></p><p><span class=font8>Table 8. Vitamin D and cardiovascular outcomes: Characteristics of RCTs [no new studies</span></p><p><span class=font8><a href=#bookmark105>in the current report].....................................................................................................................54</a></span></p><p><span class=font8>Table 9. Vitamin D and cardiovascular outcomes: Results of RCTs [no new studies in the</span></p><p><span class=font8><a href=#bookmark106>current report]...............................................................................................................................55</a></span></p><p><span class=font8>Table 10. Vitamin D and cardiovascular outcomes: Characteristics of cohort studies (updated</span></p><p><span class=font8><a href=#bookmark107>from original report).....................................................................................................................56</a></span></p><p><span class=font8>Table 11a. Vitamin D and cardiovascular outcomes: Results of cohort studies (updated from</span></p><p><span class=font8><a href=#bookmark108>original report)..............................................................................................................................65</a></span></p><p><span class=font8>Table 11b. Vitamin D and cardiovascular outcomes: Results of nested case-control studies</span></p><p><span class=font8><a href=#bookmark109>(new table)....................................................................................................................................80</a></span></p><p><span class=font8>Table 12. Vitamin D and weight: Characteristics of RCTs [no new studies in the current</span></p><p><span class=font8><a href=#bookmark110>report]............................................................................................................................................ 91</a></span></p><p><span class=font8><a href=#bookmark111>Table 13. Vitamin D and weight: &nbsp;&nbsp;&nbsp;Results of RCTs [no new studies in the current report]..........92</a></span></p><p><span class=font8>Table 14. Vitamin D and total cancer and total cancer mortality: Characteristics of RCTs</span></p><p><span class=font8><a href=#bookmark112>[no new studies in the current report]...........................................................................................96</a></span></p><p><span class=font8>Table 15. Vitamin D and total cancer and total cancer mortality: Characteristics of cohort</span></p><p><span class=font8><a href=#bookmark113>studies (updated from original report)..........................................................................................97</a></span></p><p><span class=font8>Table 16. Vitamin D and total cancer and total cancer mortality: Results of RCTs [no new</span></p><p><span class=font8><a href=#bookmark114>studies in the current report].......................................................................................................100</a></span></p><p><span class=font8>Table 17. Vitamin D and total cancer and total cancer mortality: Results of cohort studies</span></p><p><span class=font8><a href=#bookmark115>(updated from original report)....................................................................................................101</a></span></p><p><span class=font8>Table 18. Vitamin D and prostate cancer: Characteristics of observational studies (updated</span></p><p><span class=font8><a href=#bookmark116>from original report)...................................................................................................................110</a></span></p><p><span class=font8>Table 19. Vitamin D and prostate cancer: Results of observational studies (updated from</span></p><p><span class=font8><a href=#bookmark117>original report)............................................................................................................................115</a></span></p><p><span class=font8><a href=#bookmark118>Table 20. Vitamin D and colorectal cancer: Characteristics of RCTs [no new studies in the current report].............................................................................................................................123</a></span></p><p><span class=font8>Table 21. Vitamin D and colorectal cancer: Results of RCTs [no new studies in the current</span></p><p><span class=font8><a href=#bookmark119>report]..........................................................................................................................................124</a></span></p><p><span class=font8>Table 22. Vitamin D and colorectal cancer: Characteristics of observational studiesA</span></p><p><span class=font8><a href=#bookmark120>(updated from original report)....................................................................................................128</a></span></p><p><span class=font8>Table 23. Vitamin D and colorectal cancer: Results of observational studies (updated from</span></p><p><span class=font8><a href=#bookmark121>original report)............................................................................................................................132</a></span></p><p><span class=font8>Table 24. Vitamin D and colorectal adenoma: Characteristics of observational studies [no new</span></p><p><span class=font8><a href=#bookmark122>studies in the current report].......................................................................................................143</a></span></p><p><span class=font8>Table 25. Vitamin D and colorectal adenoma: Results of observational studies [no new</span></p><p><span class=font8><a href=#bookmark123>studies in the current report].......................................................................................................144</a></span></p><p><span class=font8>Table 26a. Vitamin D and breast cancer: Characteristics of nested case-control studies</span></p><p><span class=font8><a href=#bookmark124>(updated from original report)....................................................................................................148</a></span></p><p><span class=font8>Table 26b. Vitamin D and breast cancer: Characteristics of prospective cohort studies</span></p><p><span class=font8><a href=#bookmark125>(updated from original report)....................................................................................................150</a></span></p><p><span class=font8>Table 26c. Vitamin D and breast density: Characteristics of RCTs (updated from original</span></p><p><span class=font8><a href=#bookmark126>report).......................................................................................................................................... 151</a></span></p><p><span class=font8>Table 26d Vitamin D and breast density: Characteristics of nested case-control studies</span></p><p><span class=font8><a href=#bookmark127>(updated from original report)....................................................................................................151</a></span></p><p><span class=font8>Table 27a. Vitamin D and breast cancer: Results of nested case-control studies (updated</span></p><p><span class=font8><a href=#bookmark128>from original report)...................................................................................................................152</a></span></p><p><span class=font8>Table 27b. Vitamin D and breast cancer: Results of prospective cohort studies (updated</span></p><p><span class=font8><a href=#bookmark129>from original report)...................................................................................................................155</a></span></p><p><span class=font8><a href=#bookmark130>Table 27c. Vitamin D and breast density: Results of RCTs (updated from original report)......156</a></span></p><p><span class=font8>Table 27d. Vitamin D and breast density: Results of nested case-control studies (updated</span></p><p><span class=font8><a href=#bookmark131>from original report)...................................................................................................................157</a></span></p><p><span class=font8>Table 28. Vitamin D and pancreatic cancer: Characteristics of observational studies (updated</span></p><p><span class=font8><a href=#bookmark132>from original report)...................................................................................................................160</a></span></p><p><span class=font8>Table 29. Vitamin D and pancreatic cancer: Results of observational studies (updated from</span></p><p><span class=font8><a href=#bookmark133>original report)............................................................................................................................161</a></span></p><p><span class=font8>Table 30a. Vitamin D (mother) and immunologic outcomes (offspring): Characteristics</span></p><p><span class=font8><a href=#bookmark134>of cohort studies (updated from original report).........................................................................169</a></span></p><p><span class=font8>Table 30b. Vitamin D and immunologic outcomes: Characteristics of autoimmune disease</span></p><p><span class=font8><a href=#bookmark135>RCTs (updated from original report)..........................................................................................176</a></span></p><p><span class=font8>Table 30c. Vitamin D and immunologic outcomes: Characteristics of infectious disease</span></p><p><span class=font8><a href=#bookmark136>continuous RCTs (updated from original report)........................................................................176</a></span></p><p><span class=font8>Table 30d. Vitamin D and immunologic outcomes: Characteristics of infectious disease</span></p><p><span class=font8><a href=#bookmark137>dichotomous RCTs (updated from original report)....................................................................177</a></span></p><p><span class=font8>Table 31a. Vitamin D (mother) and immunologic outcomes (offspring): Results of</span></p><p><span class=font8><a href=#bookmark138>observational studies (updated from original report)..................................................................178</a></span></p><p><span class=font8>Table 31b. Vitamin D and immunologic outcomes: Results of autoimmune disease RCTs</span></p><p><span class=font8><a href=#bookmark139>(updated from original report)....................................................................................................184</a></span></p><p><span class=font8>Table 31c. Vitamin D and immunologic outcomes: Results of infectious disease RCTs</span></p><p><span class=font8><a href=#bookmark140>(continuous outcomes) (updated from original report)...............................................................184</a></span></p><p><span class=font8><a href=#bookmark141>Table 31d. Vitamin D and immunologic outcomes: Results of infectious disease RCTs (dichotomous outcomes) (updated from original report)............................................................185</a></span></p><p><span class=font8>Table 32a. Vitamin D and preeclampsia: Characteristics of observational studies (updated</span></p><p><span class=font8><a href=#bookmark142>from original report)...................................................................................................................191</a></span></p><p><span class=font8>Table 32b. Vitamin D and other pregnancy outcomes: Characteristics of observational</span></p><p><span class=font8><a href=#bookmark143>studies (updated from original report)........................................................................................193</a></span></p><p><span class=font8>Table 32c. Vitamin D and preeclampsia: Characteristics of RCTs (updated from original</span></p><p><span class=font8><a href=#bookmark144>report)..........................................................................................................................................194</a></span></p><p><span class=font8>Table 33a. Vitamin D and preeclampsia: Results of observational studies (updated from</span></p><p><span class=font8><a href=#bookmark145>original report)............................................................................................................................195</a></span></p><p><span class=font8>Table 33b. Vitamin D and other pregnancy outcomes: Results of observational studies</span></p><p><span class=font8><a href=#bookmark146>(updated from original report)....................................................................................................197</a></span></p><p><span class=font8><a href=#bookmark147>Table 33c. Vitamin D and preeclampsia: results of RCTs (updated from original report)........198</a></span></p><p><span class=font8>Table 34. Summary of systematic review of the effect of vitamin D on bone health</span></p><p><span class=font8><a href=#bookmark148>(not updated from original report)..............................................................................................201</a></span></p><p><span class=font8>Table 35a. Vitamin D and bone health: Characteristics of RCTs published after the</span></p><p><span class=font8><a href=#bookmark149>Ottawa EPC report (updated from original report).....................................................................206</a></span></p><p><span class=font8>Table 35b. Vitamin D and muscle strength: Characteristics of RCTs (updated from original</span></p><p><span class=font8><a href=#bookmark150>report).......................................................................................................................................... 207</a></span></p><p><span class=font8>Table 35c. Vitamin D and muscle strength: Characteristics of prospective cohorts (updated</span></p><p><span class=font8><a href=#bookmark151>from original report)...................................................................................................................208</a></span></p><p><span class=font8>Table 35d. Vitamin D and bone health: Characteristics of observational studies published</span></p><p><span class=font8><a href=#bookmark152>after the Ottawa EPC report (updated from original report).......................................................209</a></span></p><p><span class=font8>Table 36a. Vitamin D and bone health: Results of RCTs published after the Ottawa EPC</span></p><p><span class=font8><a href=#bookmark153>report (updated from original report)..........................................................................................212</a></span></p><p><span class=font8>Table 36b. Vitamin D and muscle strength: Results of RCTs (updated from original</span></p><p><span class=font8><a href=#bookmark154>report).......................................................................................................................................... 214</a></span></p><p><span class=font8>Table 36c. Vitamin D and muscle strength: Results of prospective cohorts (updated</span></p><p><span class=font8><a href=#bookmark155>from original report)...................................................................................................................217</a></span></p><p><span class=font8>Table 36d. Vitamin D and bone health: Results of observational studies published</span></p><p><span class=font8><a href=#bookmark156>after the Ottawa EPC report (updated from original report).......................................................221</a></span></p><p><span class=font8>Table 37. Summary of systematic review on vitamin D supplementation and all-cause</span></p><p><span class=font8><a href=#bookmark157>mortality (not updated from original report)...............................................................................225</a></span></p><p><span class=font8>Table 38. Vitamin D and all-cause mortality: Characteristics of cohort studies (updated</span></p><p><span class=font8><a href=#bookmark158>from original report)...................................................................................................................228</a></span></p><p><span class=font8>Table 39. Vitamin D and all-cause mortality: Results of cohort studies (updated from</span></p><p><span class=font8><a href=#bookmark159>original report)............................................................................................................................233</a></span></p><p><span class=font8>Table 40. Vitamin D and hypertension: Characteristics of cohort studies (updated</span></p><p><span class=font8><a href=#bookmark160>from original report)...................................................................................................................245</a></span></p><p><span class=font8>Table 41. Vitamin D and hypertension: Results of cohort and nested case-control studies</span></p><p><span class=font8><a href=#bookmark161>(updated from original report) .................................................................................................... 246</a></span></p><p><span class=font8>Table 42. Vitamin D and blood pressure: Characteristics of RCTs (updated from original</span></p><p><span class=font8><a href=#bookmark162>report)..........................................................................................................................................251</a></span></p><p><span class=font8><a href=#bookmark163>Table 43. Vitamin D and blood pressure: Results of RCTs........................................................255</a></span></p><p><span class=font8>Table 44. Vitamin D and bone mineral density: Characteristics of RCTs published</span></p><p><span class=font8><a href=#bookmark164>after the Ottawa EPC report (updated from original report).......................................................264</a></span></p><p><span class=font8><a href=#bookmark165>Table 45. Vitamin D and bone mineral density or bone mineral contents: Results of RCTs published after the Ottawa EPC report (updated from original report)......................................267</a></span></p><p><span class=font8>Table 46. Combined vitamin D and calcium and cardiovascular outcomes: Characteristics</span></p><p><span class=font8><a href=#bookmark166>of RCTs (formerly Table 85) (updated from original report).....................................................277</a></span></p><p><span class=font8>Table 47. Combined vitamin D and calcium and cardiovascular outcomes: Results of RCTs</span></p><p><span class=font8><a href=#bookmark167>(formerly Table 86) (updated from original report)....................................................................278</a></span></p><p><span class=font8>Table 48. Combined vitamin D and calcium and weight: Characteristics of RCTs (formerly</span></p><p><span class=font8><a href=#bookmark168>Table 87) (no new studies in the current report).........................................................................282</a></span></p><p><span class=font8>Table 49. Combined vitamin D and calcium and weight: Results of RCTs (formerly Table 88)</span></p><p><span class=font8><a href=#bookmark169>[no new studies in the current report].........................................................................................283</a></span></p><p><span class=font8>Table 50. Combined vitamin D and calcium and total cancer incidence: Characteristics</span></p><p><span class=font8><a href=#bookmark170>of RCTs (formerly Table 89) (updated from original report).....................................................285</a></span></p><p><span class=font8>Table 51. Combined vitamin D and calcium and total cancer incidence: Results of RCTs</span></p><p><span class=font8><a href=#bookmark171>(formerly Table 90) (updated from original report)....................................................................286</a></span></p><p><span class=font8>Table 52. Combined vitamin D with calcium and colorectal cancer: Characteristics</span></p><p><span class=font8><a href=#bookmark172>of RCTs (formerly Table 91) [no new studies in the current report]..........................................289</a></span></p><p><span class=font8>Table 53. Combined vitamin D with calcium and colorectal cancer: Results of RCTs</span></p><p><span class=font8><a href=#bookmark173>(formerly Table 92) [no new studies in the current report]........................................................290</a></span></p><p><span class=font8>Table 54. Combined vitamin D and calcium and breast cancer outcomes: Characteristics</span></p><p><span class=font8><a href=#bookmark174>of RCTs (formerly Table 93) [no new studies in the current report]..........................................293</a></span></p><p><span class=font8>Table 55. Combined vitamin D and calcium and breast cancer outcomes: Results of RCTs</span></p><p><span class=font8><a href=#bookmark175>(formerly Table 94) [no new studies in the current report]........................................................294</a></span></p><p><span class=font8>Table 56. Combined vitamin D and calcium and preeclampsia: Characteristics of RCTs</span></p><p><span class=font8><a href=#bookmark176>(formerly Table 95) [no new studies in the current report]........................................................296</a></span></p><p><span class=font8>Table 57. Combined vitamin D and calcium and preeclampsia: Results of RCTs (formerly</span></p><p><span class=font8><a href=#bookmark177>Table 96) [no new studies in the current report].........................................................................297</a></span></p><p><span class=font8>Table 58. Combined vitamin D and calcium and bone health: Characteristics of RCTs</span></p><p><span class=font8><a href=#bookmark178>published after the Ottawa EPC report (formerly Table 97) (updated from original report).....301</a></span></p><p><span class=font8>Table 59. Combined vitamin D and calcium and bone health: Results of RCTs published after the Ottawa EPC report (stress fracture) (formerly Table 98) (updated from original</span></p><p><span class=font8><a href=#bookmark179>report)..........................................................................................................................................302</a></span></p><p><span class=font8>Table 60. Combined vitamin D and calcium and bone health: Results of RCTs published after the Ottawa EPC report (performance measures) (formerly Table 99) (updated from</span></p><p><span class=font8><a href=#bookmark180>original report)............................................................................................................................305</a></span></p><p><span class=font8>Table 61. Combined vitamin D and calcium and incident hypertension: Characteristics</span></p><p><span class=font8><a href=#bookmark181>of RCTs [no new studies in the current report]...........................................................................311</a></span></p><p><span class=font8>Table 62. Combined vitamin D and calcium and incident hypertension: Results of RCTs</span></p><p><span class=font8><a href=#bookmark182>[no new studies in the current report].........................................................................................312</a></span></p><p><span class=font8>Table 63. Combined vitamin D and calcium and blood pressure: Characteristics of RCTs</span></p><p><span class=font8><a href=#bookmark183>(formerly Table 102) [no new studies in the current report]......................................................315</a></span></p><p><span class=font8>Table 64. Combined vitamin D and calcium and blood pressure: Results of RCTs (formerly</span></p><p><span class=font8><a href=#bookmark184>Table 103) [no new studies in the current report].......................................................................316</a></span></p><p><span class=font8>Table 65. Combined vitamin D and calcium and bone mineral density/content: Characteristics of RCTs published after the Ottawa EPC report (formerly Table 104) (no new studies in the current</span></p><p><span class=font8><a href=#bookmark185>report).......................................................................................................................................... 320</a></span></p><p><span class=font8>Table 66. Combined vitamin D and calcium and bone mineral density/content: Results</span></p><p><span class=font8>of RCTs published after the Ottawa EPC report (formerly Table 105) (no new studies</span></p><p><span class=font8><a href=#bookmark186>in the current report)...................................................................................................................322</a></span></p><p><span class=font8>Table 67. The relationship between vitamin D3 daily doses and changes in 25(OH)D</span></p><p><span class=font8>concentrations in RCTs (formerly Table 106) (updated from original report)....................</span></p><p><span class=font8><a href=#bookmark187>Table 68. Adverse events reported in RCTs (formerly Table 107) (updated from original report)..........................................................................................................................................342</a></span></p><p><span class=font8 style=font-weight:700>Figures</span></p><p><span class=font8>Figure 1. Summary of the vitamin D endocrine system [updated figure for the current report] .... 4 Figure 2. Generic analytic framework to assist formulation of Key Questions for the</span></p><p><span class=font8><a href=#bookmark188>development of DRIs......................................................................................................................8</a></span></p><p><span class=font8>Figure 3. Analytic framework for vitamin D with or without calcium: EARs [revised for the</span></p><p><span class=font8><a href=#bookmark189>current report]...............................................................................................................................11</a></span></p><p><span class=font8>Figure 4. Analytic framework for vitamin D with or without calcium ULs [revised for</span></p><p><span class=font8><a href=#bookmark190>the current report].........................................................................................................................12</a></span></p><p><span class=font8><a href=#bookmark191>Figure 5a. Literature flow for the original report..........................................................................29</a></span></p><p><span class=font8><a href=#bookmark192>Figure 5b. Literature flow for the current report...........................................................................30</a></span></p><p><span class=font8>Figure 6a. Cardiovascular outcomes risk stratified by vitamin D concentration for combined</span></p><p><span class=font8><a href=#bookmark193>and general CV outcomes.............................................................................................................81</a></span></p><p><span class=font8>Figure 6b. Cardiovascular outcomes risk stratified by vitamin D concentration for combined</span></p><p><span class=font8><a href=#bookmark194>and general CV outcomes by gender............................................................................................82</a></span></p><p><span class=font8>Figure 6c. Cardiovascular outcomes risk stratified by vitamin D concentration for CV</span></p><p><span class=font8><a href=#bookmark195>mortality ........................................................................................................................................ 83</a></span></p><p><span class=font8>Figure 6d. Cardiovascular outcomes risk stratified by vitamin D concentration for CV</span></p><p><span class=font8><a href=#bookmark196>mortality by gender.......................................................................................................................84</a></span></p><p><span class=font8>Figure 6e. Cardiovascular outcomes risk stratified by vitamin D concentration for</span></p><p><span class=font8><a href=#bookmark197>myocardial infarction....................................................................................................................85</a></span></p><p><span class=font8>Figure 6g. Cardiovascular outcomes risk stratified by vitamin D concentration</span></p><p><span class=font8><a href=#bookmark198>for fatal stroke...............................................................................................................................87</a></span></p><p><span class=font8>Figure 6h. Cardiovascular outcomes risk stratified by vitamin D concentration for</span></p><p><span class=font8><a href=#bookmark199>congestive heart failure.................................................................................................................88</a></span></p><p><span class=font8>Figure 7. Prostate cancer risk stratified by vitamin D concentration (updated</span></p><p><span class=font8><a href=#bookmark200>from original report)...................................................................................................................121</a></span></p><p><span class=font8><a href=#bookmark201>Figure 8. Colorectal cancer risk stratified by vitamin D concentration......................................139</a></span></p><p><span class=font8><a href=#bookmark202>Figure 9. Colon cancer risk stratified by vitamin &nbsp;&nbsp;&nbsp;D concentration.............................................140</a></span></p><p><span class=font8><a href=#bookmark203>Figure 10. Rectal cancer risk stratified by vitamin D &nbsp;&nbsp;&nbsp;concentration..........................................141</a></span></p><p><span class=font8>Figure 11. Forest plot of trials of combined vitamin D and calcium supplementation</span></p><p><span class=font8><a href=#bookmark204>and effects on all-cause mortality (formerly Figure 22)............................................................. 309</a></span></p><p><span class=font8>Figure 12. Relationship between doses of vitamin D3 supplementation and net changes</span></p><p><span class=font8><a href=#bookmark205>in serum 25(OH)D concentrations in RCTs (formerly Figure 23)............................................. 332</a></span></p><p><span class=font8>Figure 13. Relationship between doses of vitamin D3 supplementation and net changes in serum 25(OH)D concentrations in RCTs by baseline vitamin D status among adults</span></p><p><span class=font8><a href=#bookmark206>(formerly Figure 24) ................................................................................................................... 333</a></span></p><p><span class=font8>Figure 14. Relationship between doses of vitamin D3 supplementation and net changes in serum 25(OH)D concentrations in RCTs by duration of supplementation among adults</span></p><p><span class=font8><a href=#bookmark207>(formerly Figure 25) ................................................................................................................... 334</a></span></p><p><span class=font8><a href=#bookmark208>Figure 15. Relationship between doses of vitamin D3 supplementation and net changes in serum 25(OH)D concentrations in RCTs by assay type (new figure)....................................335</a></span></p><p><span class=font8 style=font-weight:700>Appendixes</span></p><p><span class=font8>Appendix A. Search Strategy for Primary Studies Appendix B. Search Strategy for Systematic Reviews&nbsp;Appendix C. Evidence Tables for the Current Report</span></p><p><span class=font8>Appendix D. Evaluation of Existing Systematic Reviews and Evidence Tables of the Qualified Systematic Reviews</span></p><p><span class=font8>Appendix E. Blank Data Extraction Form and Quality Assessment Checklists Appendix F. Excluded Studies</span></p><p><span class=font8>Appendix G. Serum Vitamin D Assay Reporting in Randomized Controlled Trials (RCTs) Appendix H. Studies Reporting Key Outcomes Stratified by Vitamin D Assay Method</span></p><h1><a name=bookmark9></a><span class=font5 style=font-weight:700>Executive Summary</span></h1><h2><a name=bookmark11></a><span class=font4 style=font-weight:700>Background</span></h2><p><span class=font8>In 2009, the Tufts Evidence-based Practice Center (EPC) conducted a systematic review of the scientific literature on vitamin D and calcium intakes as related to status indicators and health&nbsp;outcomes. The purpose of this report was to guide the nutrition recommendations of the Institute&nbsp;of Medicine (IOM) Dietary Reference Intakes (DRIs).</span></p><p><span class=font8>In September 2007, the IOM held a conference to examine the lessons learned from developing DRIs, and future challenges and best practices for developing DRIs. The conference&nbsp;concluded that systematic reviews would enhance the transparency and rigor of DRI committee&nbsp;deliberations. With this framework in mind, the Agency for Healthcare Research and Quality&nbsp;(AHRQ) EPC program invited the Tufts EPC to perform the systematic review of vitamin D and&nbsp;calcium.</span></p><p><span class=font8>In May and September 2007, two conferences were held on the effect of vitamin D on health. Subsequently, a working group of scientists from the United States and Canadian Governments&nbsp;convened to determine whether enough new research had been published since the 1997 vitamin&nbsp;D DRI to justify an update. Upon reviewing the conference proceedings and results from a recent&nbsp;systematic review, the group concluded that sufficient new data beyond bone health had been&nbsp;published. Areas of possible relevance included new data on bone health for several of the life&nbsp;stage groups, reports on potential adverse effects, dose-response relations between intakes and&nbsp;circulating 25-hydroxyvitamin D (25(OH)D) concentrations and between 25(OH)D&nbsp;concentrations, and several health outcomes.</span></p><p><span class=font8 style=font-weight:700>In 2013, in preparation for a project the National Institutes of Health Office of Dietary Supplements (NIH/ODS) was undertaking related to evidence-based decisionmaking for&nbsp;vitamin D in primary care, which will include information from this updated systematic&nbsp;review on vitamin D and health outcomes, the ODS and AHRQ requested an update to the&nbsp;2009 systematic review that will incorporate the findings of studies on vitamin D and&nbsp;vitamin D administered in conjunction with calcium that have been conducted since the&nbsp;release of the 2009 review. This updated report assesses all outcomes assessed in the&nbsp;original 2009 report (for vitamin D and vitamin D plus calcium) with the exception of&nbsp;outcomes pertaining to body weight and composition and postnatal growth. This updated&nbsp;report also describes the assay methodologies used in trials included in the original review&nbsp;as well as any newly included studies that report on the effect of vitamin D&nbsp;supplementation on serum 25(OH)D concentrations, to permit a comparison of dose-response outcomes by assay method. The text of the original 2009 report has been&nbsp;preserved essentially in its entirety: Text and tables that report outcomes of calcium&nbsp;supplementation only have been omitted. Here and in the remainder of the report, updated&nbsp;methods, study details, and findings are presented in boldface type. The protocol for the&nbsp;updated report was posted on the AHRQ Web site for public comment, which can be found&nbsp;at <a href="http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&amp;productID=1529">http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&amp;productID=1529</a>.</span></p><p><span class=font8 style=font-weight:700>This update was requested by the sponsor in anticipation of a conference focused on the evaluation of evidence related to vitamin D and health outcomes, but the update can also be&nbsp;helpful to other stakeholders. The sponsor’s interest was to determine whether the&nbsp;inclusion of newer relevant data that became available during the period following the&nbsp;close of the 2009 review would alter or continue to support the conclusions of the 2009</span></p><p><span class=font8 style=font-weight:700>report. The sponsor’s interest did not include the topic area of calcium alone or of growth and body weight as they relate to vitamin D, so for reasons of cost these components of the&nbsp;original report were not included in this review.</span></p><p><span class=font8>The </span><span class=font8 style=font-weight:700>original </span><span class=font8>report included a systematic review of health outcomes relating to vitamin D and calcium intakes, both alone and in combination; </span><span class=font8 style=font-weight:700>the current report updates that&nbsp;systematic review for outcomes relating to intakes of vitamin D alone or in combination&nbsp;with calcium</span><span class=font8>. The executive summary provides a high-level overview of the findings of the&nbsp;systematic review; </span><span class=font8 style=font-weight:700>the summary of studies included in the current report is in boldface type</span><span class=font8>.&nbsp;Recommendations and potential revisions of nutrient reference values (i.e., the new DRIs) based&nbsp;on this review are the responsibility of the IOM committee and are beyond the scope of this&nbsp;report.</span></p><h2><a name=bookmark16></a><span class=font4 style=font-weight:700>Methods</span></h2><p><span class=font8>This systematic review—</span><span class=font8 style=font-weight:700>both the original and the update</span><span class=font8>—answers key scientific questions on how dietary vitamin D and calcium intakes affect health outcomes. Federal&nbsp;sponsors defined the Key Questions, and a technical expert panel was assembled to refine the&nbsp;questions and establish inclusion and exclusion criteria for the studies to be reviewed. In&nbsp;answering the questions, we followed the general methodologies described in AHRQ’s “Methods&nbsp;Guide for Comparative Effectiveness Reviews.” The </span><span class=font8 style=font-weight:700>original </span><span class=font8>report </span><span class=font8 style=font-weight:700>was </span><span class=font8>provided to an IOM&nbsp;committee charged with updating vitamin D and calcium DRIs. </span><span class=font8 style=font-weight:700>The current report will be&nbsp;made available to NIH/ODS, which are the sponsors of this update. Neither </span><span class=font8>this report </span><span class=font8 style=font-weight:700>nor&nbsp;the original </span><span class=font8>makes clinical or policy recommendations.</span></p><p><span class=font8>The population of interest is the “general population” of otherwise healthy people to whom DRI recommendations are applicable. The Key Questions addressed in </span><span class=font8 style=font-weight:700>the original report and&nbsp;</span><span class=font8>this </span><span class=font8 style=font-weight:700>updated </span><span class=font8>report are as follows:</span></p><p><span class=font4>Key Question 1. What is the effect of vitamin D, calcium (</span><span class=font4 style=font-weight:700>excluded from current/updated report)</span><span class=font4>, or combined vitamin D&nbsp;and calcium intakes on clinical outcomes, including growth,&nbsp;cardiovascular diseases, body weight outcomes, cancer, immune&nbsp;function, pregnancy or birth outcomes, mortality, fracture, renal&nbsp;outcomes, and soft tissue calcification (</span><span class=font4 style=font-weight:700>the current report&nbsp;excludes the outcomes of postnatal growth and weight&nbsp;outcomes)</span><span class=font4>?</span></p><p><span class=font4>Key Question 2. What is the effect of vitamin D, calcium </span><span class=font4 style=font-weight:700>(excluded from current report), </span><span class=font4>or combined vitamin D and&nbsp;calcium intakes on surrogate or intermediate outcomes, such as&nbsp;hypertension, blood pressure, and bone mineral density?</span></p><p><span class=font4>Key Question 3. What is the association between serum 25(OH)D concentrations or calcium balance </span><span class=font4 style=font-weight:700>(excluded from current&nbsp;report) </span><span class=font4>and clinical outcomes?</span></p><p><span class=font4>Key Question 4. What is the effect of vitamin D or combined vitamin D and calcium intakes on serum 25(OH)D&nbsp;concentrations?</span></p><p><span class=font4>Key Question 5. What is the association between serum 25(OH)D concentrations and surrogate or intermediate outcomes?</span></p><p><span class=font8 style=font-weight:700>The original report </span><span class=font8>performed electronic searches of the medical literature (1969-April 2009) to identify publications addressing the aforementioned questions. We set specific&nbsp;eligibility criteria. We reviewed primary studies and existing systematic reviews. When a&nbsp;qualifying systematic review was available, we generally relied on the systematic review, and&nbsp;updated it by reviewing studies published after its completion. </span><span class=font8 style=font-weight:700>The search strategy of peer-reviewed literature for the updated report duplicated that used in the original 2009 report&nbsp;to the extent possible, excluding the searches specific to calcium only and those for the&nbsp;outcomes of growth and weight. Searches for the current report covered the time period&nbsp;from January 2008 to April 2013.</span></p><p><span class=font8>We rated the primary studies using a three-grade system (A, B, or C), evaluating each type of study design (i.e., randomized controlled trial or RCT, cohort, and nested case-control). Grade A&nbsp;studies have the least bias, and their results are considered valid within the limits of&nbsp;interpretation for that study design. Grade B studies are susceptible to some bias, but the amount&nbsp;is not sufficient to invalidate the results. Grade C studies have significant bias that may&nbsp;invalidate the results.</span></p><h2><a name=bookmark56></a><span class=font4 style=font-weight:700>Results</span></h2><p><span class=font8 style=font-weight:700>The original report </span><span class=font8>screened for eligibility a total of 18,479 citations that were identified through our searches, perusal of reference lists, and suggestions from experts. Of 652&nbsp;publications that were reviewed in full text, 165 primary study articles and 11 systematic reviews&nbsp;were included in the systematic review. Their results are summarized in this report.</span></p><p><span class=font8 style=font-weight:700>For the current report, we screened for eligibility a total of 6,165 citations identified through electronic searches, reference mining, and handsearches for articles suggested by&nbsp;experts. Of 1,107 publications reviewed in full text, 154 new articles (reporting on 156&nbsp;studies) and two existing systematic reviews were included in this systematic review. The&nbsp;results are summarized in this report in boldface type. Table A summarizes the numbers of&nbsp;studies included for each outcome for both the original and the current report, stratified by&nbsp;study design, as well as the conclusions.</span></p><h3><a name=bookmark209></a><span class=font10 style=font-weight:700>Vitamin D</span></h3><h3><a name=bookmark62></a><span class=font3 style=font-weight:700>Vitamin D and Growth</span></h3><p><span class=font8 style=font-weight:700>For the current report, we identified five new RCTs (reported in four articles) and two new observational studies that evaluated intake of or exposure to vitamin D, respectively,&nbsp;on birth weight and/or length. In the current report, five RCTs (reported in four articles)&nbsp;reported on the effect of vitamin D supplementation during pregnancy on birth weight&nbsp;and/or length. One U.S. RCT divided 350 women who were already receiving prenatal&nbsp;vitamins that provided 400 international units (IU) vitamin D per day at 16 weeks gestation&nbsp;or earlier into three groups, who were given an additional 0, 1,600, or 3,600 IU vitamin D&nbsp;per day through the remainder of gestation; the study found no difference in birth weight&nbsp;among interventional arms (rated A).<sup>1</sup> The second study, a pseudo-RCT conducted in&nbsp;India, divided 140 pregnant women at 12 to 24 weeks gestation into two groups: one was&nbsp;administered one 1,500 microgram dose of vitamin D and the other received two doses of</span></p><p><span class=font8 style=font-weight:700>3,000 micrograms vitamin D (a group of untreated women who were 24 weeks pregnant or&nbsp;more served as the controls); both of the treated groups gave birth to infants who were&nbsp;significantly heavier than the usual care group (p=0.003) (rated C). The third RCT, the&nbsp;AViDD study conducted in Bangladesh, randomly divided 160 women at 26 to less than 30&nbsp;weeks gestation to receive 35,000 IU vitamin D per week or no supplement; no difference&nbsp;was seen in birth weight or length, although the study was not powered to see differences in&nbsp;these outcomes (rated A). For the fourth and fifth studies, data from the National Institute&nbsp;of Child Health and Disease (NICHD) and Thrasher Research Fund Vitamin D<sub>3&nbsp;</sub>Supplementation studies—in which pregnant women were randomized to receive 0, 2,000,&nbsp;or 4,000 IU vitamin D per day in addition to their prenatal vitamins—were analyzed in&nbsp;combination: No differences were observed in birth weight among the groups (rated B). Of&nbsp;the two observational cohort studies, one observed a significant association of second&nbsp;trimester maternal vitamin D concentrations (rated B) and one found no association (rated&nbsp;A).</span></p><p><span class=font8 style=font-weight:700>As reviewed in the original report, s</span><span class=font8>ix RCTs, one nonrandomized comparative intervention study, and two observational studies evaluated intake of vitamin D or serum 25(OH)D&nbsp;concentrations and growth parameters in infants and children. The studies had diverse&nbsp;populations and methodological approaches. One RCT and one observational study were rated&nbsp;B; seven studies were rated C. Most studies found no significant associations between either&nbsp;maternal or offspring vitamin D intake and offspring’s weight or height, but two C-rated&nbsp;intervention studies from the same center in India found a significant effect of total maternal&nbsp;vitamin D intake of 1.2 million IU and increased infant birth weights.</span></p><h3><a name=bookmark61></a><span class=font3 style=font-weight:700>Vitamin D and Cardiovascular Events</span></h3><p><span class=font8 style=font-weight:700>One good-quality existing systematic review of prospective studies identified for the current report found a significant association between low serum 25(OH)D concentrations&nbsp;and a number of clinical cardiovascular outcomes, including total cardiovascular disease,&nbsp;coronary heart disease, cardiovascular disease mortality, and stroke. No RCTs were&nbsp;identified for the current report that evaluated the effects of vitamin D on clinical&nbsp;cardiovascular disease outcomes. New observational studies identified for the current&nbsp;report (7 for total cardiovascular events, 17 for cardiovascular death, 2 for ischemic heart&nbsp;disease, 6 for myocardial infarction, 8 for stroke, and 3 for fatal stroke) found mixed&nbsp;associations between 25(OH)D and all of these outcomes.</span></p><p><span class=font8 style=font-weight:700>As reviewed in the original report</span><span class=font8>, one B-rated RCT and four cohort studies (two rated A, two C) have analyzed the association between serum 25(OH)D concentrations and risk of&nbsp;cardiovascular events. The RCT, which compared vitamin D<sub>3</sub> (100,000 IU every 4 months) or&nbsp;placebo for 5 years in elderly people, found no significant difference in event rates for various&nbsp;cardiovascular outcomes, including total events and cardiovascular deaths. In two of the cohort&nbsp;studies, significant associations were found between progressively lower 25(OH)D&nbsp;concentration—analyzed at upper thresholds of 37.5 and 75 nmol/L—and progressively&nbsp;increased risk of any cardiovascular event. The other two cohort studies found no significant&nbsp;associations between serum 25(OH)D concentrations and cardiovascular death, myocardial&nbsp;infarction, or stroke.</span></p><h3><a name=bookmark60></a><span class=font3 style=font-weight:700>Vitamin D and Body Weight</span></h3><p><span class=font8 style=font-weight:700>The current report did not assess the association between vitamin D and body weight. For the original report, n</span><span class=font8>o studies evaluated serum 25(OH)D concentrations and risk of obesity&nbsp;or overweight. We evaluated only RCTs for changes in body weight. Three RCTs (one rated B,&nbsp;two rated C) compared a range of dosages (300 IU/d to 120,000 IU every 2 weeks) to placebo.&nbsp;Vitamin D supplementation had no significant effect on weight.</span></p><h3><a name=bookmark63></a><span class=font3 style=font-weight:700>Vitamin D and Cancer</span></h3><h4><a name=bookmark210></a><span class=font9 style=font-weight:700>Cancer From All Causes</span></h4><p><span class=font8 style=font-weight:700>No new RCTs were identified for the current report that addressed the effect of vitamin D or vitamin D combined with calcium on the risk for total cancer or cancer mortality.</span></p><p><span class=font8 style=font-weight:700>Two new cohort studies found no association between total (all-cause) cancer incidence and serum 25(OH)D concentrations (rated A and B). Ten new cohort studies and one new&nbsp;nested case-control study addressed the association of serum 25(OH)D concentrations and&nbsp;cancer mortality. Five of the cohort studies (one rated A, four rated B) observed no&nbsp;association of serum 25(OH)D concentration with total cancer mortality. Three cohort&nbsp;studies and the nested case-control study observed a trend toward increased risk with&nbsp;decreased serum 25(OH)D (all rated B). One analysis using updated Third National Health&nbsp;and Nutrition Examination Survey (NHANES III) data (rated B) observed a trend toward&nbsp;increasing risk for death with increasing serum 25(OH)D among men at higher latitudes&nbsp;whose blood was drawn in summer but the reverse in women. One cohort study observed a&nbsp;U-shaped association of increasing mortality with both low and high serum 25(OH)D.</span></p><p><span class=font8 style=font-weight:700>The original report </span><span class=font8>identified two B-rated RCTs and an analysis of the NHANES database (two publications, rated B and C). Both RCTs were conducted in older adults (postmenopausal&nbsp;women in one and people >70 years in the other). They found no significant effects for vitamin&nbsp;D supplementation (approximately 1,500 IUs per day or 100,000 IU every 4 months). Analyses&nbsp;of NHANES III showed no significant association between baseline serum 25(OH)D&nbsp;concentrations and total cancer mortality.</span></p><h4><a name=bookmark211></a><span class=font9 style=font-weight:700>Prostate Cancer</span></h4><p><span class=font8 style=font-weight:700>In the current report, four new nested case-control studies (two rated A, two rated B) and one new prospective cohort study (rated B) found no association between baseline&nbsp;serum 25(OH)D concentrations and risk for prostate cancer. Two new nested case-control&nbsp;studies (both rated B) observed a trend between higher serum vitamin D concentrations&nbsp;and increasing risk for prostate cancer. In one study this increase was seen only among&nbsp;men whose sera were sampled in summer or autumn; in the other study, this trend was&nbsp;observed only when participants were divided by quartiles of 25(OH)D concentration, but&nbsp;not when they were divided by categories of vitamin D sufficiency (concentrations less than&nbsp;50 nmol/L being considered deficient, 50-75 nmol/L insufficient, and 75-125 nmol/L&nbsp;considered sufficient).</span></p><p><span class=font8 style=font-weight:700>In the original report, </span><span class=font8>12 nested case-control studies (3 rated B, 9 C) evaluated the association of baseline serum 25(OH)D concentrations and prostate cancer risk. No eligible</span></p><p><span class=font8>RCTs were identified. Eight of the nested case-control studies found no statistically significant dose-response relationship between serum 25(OH)D concentrations and the risk of prostate&nbsp;cancer. One C-rated study found a significant association between lower baseline serum&nbsp;25(OH)D concentrations (&lt;30 compared with >55 nmol/L) and higher risk of prostate cancer.&nbsp;Another C-rated study suggested the possibility of a U-shaped association between baseline&nbsp;serum 25(OH)D concentrations and the risk of prostate cancer (i.e., lower and higher serum&nbsp;25(OH)D concentrations were associated with an increased risk of prostate cancer compared&nbsp;with that of the in between reference level).</span></p><h4><a name=bookmark212></a><span class=font9 style=font-weight:700>Colorectal Cancer</span></h4><p><span class=font8 style=font-weight:700>No new RCTs and cohort studies that addressed the effect of vitamin D on colorectal cancer mortality or incidence were identified for the current report. Three new nested&nbsp;case-control studies (two rated A, one rated B) found trends of increasing colorectal cancer&nbsp;incidence with decreasing 25(OH)D concentrations. One nested case-control study (rated&nbsp;B) found no association between colorectal cancer and 25(OH)D. Two of these nested case-control studies (both rated B) also examined colon and rectal cancer as separate outcomes.&nbsp;One study reported a significant negative trend between 25(OH)D and colon cancer risk&nbsp;and the other found a nonsignificant negative trend. For rectal cancer, the same two studies&nbsp;reported either a negative trend or a small but nonsignificant negative trend with&nbsp;25(OH)D.</span></p><p><span class=font8 style=font-weight:700>The original report </span><span class=font8>identified one B-rated RCT, one B-rated cohort study, and seven nested case-control studies (five rated B, two C) that evaluated the association between vitamin D&nbsp;exposure and colorectal cancer. The RCT of elderly population reported no significant difference&nbsp;in colorectal cancer incidence or mortality with or without vitamin D</span><span class=font6>3</span><span class=font8> supplements over 5 years&nbsp;of followup. Most nested case-control studies found no significant associations between serum&nbsp;25(OH)D concentrations and risk of colorectal cancer incidence or mortality. However, two of&nbsp;the three B-rated nested case-control studies in women found statistically significant trends&nbsp;between higher serum 25(OH)D concentrations and lower risk of colorectal cancer, but no&nbsp;individual quantile of serum 25(OH)D concentration had a significantly increased risk of&nbsp;colorectal cancer (compared with the reference quantile). The B-rated cohort study of women&nbsp;also suggested an association between higher serum 25(OH)D concentrations (>50 nmol/L) and&nbsp;lower risk of colorectal cancer mortality. The studies of men or of both sexes, and of specific&nbsp;cancers, did not have consistent findings of associations.</span></p><h4><a name=bookmark213></a><span class=font9 style=font-weight:700>Colorectal Polyps</span></h4><p><span class=font8 style=font-weight:700>No new studies were identified for the current report that assessed the association between colorectal polyps and serum concentrations of 25(OH)D.</span></p><p><span class=font8 style=font-weight:700>For the original report</span><span class=font8>, one B-rated nested case-control study in women found no significant association between serum 25(OH)D concentrations and risk of colorectal polyps. No&nbsp;RCTs evaluated this outcome.</span></p><h4><a name=bookmark214></a><span class=font9 style=font-weight:700>Breast Cancer</span></h4><p><span class=font8 style=font-weight:700>Eight new observational studies that assessed the association between 25(OH)D and breast cancer were identified for the current report. Two cohort and four nested case-control studies found no association (three rated A, three rated B). Two nested case-control</span></p><p><span class=font8 style=font-weight:700>studies found increasing risk of breast cancer with decreasing 25(OH) concentrations (both rated B).</span></p><p><span class=font8 style=font-weight:700>One new observational study that assessed the association between 25(OH)D and breast cancer-specific mortality was also identified. This cohort study found no association (rated&nbsp;B).</span></p><p><span class=font8 style=font-weight:700>Two new studies, an RCT that examined the effect of vitamin D and calcium intake on breast density and a nested case-control study that assessed the association of serum&nbsp;25(OH)D with breast density, were identified. The RCT found a decrease in percent&nbsp;mammographic density among women who had greater than or equal to 400 IU per day&nbsp;total vitamin D intake (rated A). The nested case-control found lower risk of increased&nbsp;mammographic density with 25(OH) concentrations above the first quartile (rated B).</span></p><p><span class=font8 style=font-weight:700>In the original report</span><span class=font8>, one cohort compared serum 25(OH)D concentrations and the risk of breast cancer mortality, and two nested case-control studies compared 25(OH)D concentrations&nbsp;and the incidence of breast cancer. All three studies were rated B. The NHANES III analysis&nbsp;reported a significant decrease in breast cancer mortality during 9 years of followup in those with&nbsp;baseline serum 25(OH)D concentration greater than 62 nmol/L. However, during 7 to 12 years of&nbsp;followup, the nested case-control studies found no significant relationship between serum&nbsp;25(OH)D concentration and risk of breast cancer diagnosis in either premenopausal or&nbsp;postmenopausal women.</span></p><h4><a name=bookmark215></a><span class=font9 style=font-weight:700>Pancreatic Cancer</span></h4><p><span class=font8 style=font-weight:700>For the current report, a new pooled nested case-control study within eight cohorts found an association between 25(OH)D concentration and pancreatic cancer (rated B).&nbsp;Individuals with 25(OH)D concentration greater than or equal to 100 nmol/L had greater&nbsp;risk of pancreatic cancer incidence compared with those with 25(OH)D less than 25&nbsp;nmol/L.</span></p><p><span class=font8 style=font-weight:700>For the original report, </span><span class=font8>two A-rated nested case-control studies evaluated the association of serum 25(OH)D concentrations and pancreatic cancer. No relevant RCTs were identified. One&nbsp;study of male smokers found a statistically significant relationship between increasing serum&nbsp;25(OH)D concentration (>65.5 vs. &lt;32 nmol/L) and higher risk for pancreatic cancer, and the&nbsp;subanalysis of the second study found an increased risk of pancreatic cancer among study&nbsp;participants with higher 25(OH)D concentrations (>78.4 nmol/L) compared with lower (&lt;49.3&nbsp;nmol/L) concentrations only in those living in low residential ultraviolet B exposure areas.</span></p><h3><a name=bookmark64></a><span class=font3 style=font-weight:700>Vitamin D and Immunologic Outcomes</span></h3><p><span class=font8 style=font-weight:700>The current report identified four new RCTs that assessed the effect of supplemental vitamin D on infectious illnesses and nine cohort studies that assessed the association&nbsp;between serum 25(OH)D concentrations and risk for infectious illnesses. RCTs of infants&nbsp;and adults reported no significant effect of supplementation on the risk for upper&nbsp;respiratory infections (one rated A; three rated B). Three new prospective cohort studies&nbsp;observed an association between low cord blood 25(OH)D concentrations and increased&nbsp;risk for respiratory infections at 3 to 6 months of age, in New Zealand, China, and the&nbsp;Netherlands, respectively (all rated B). Two studies of school-age children observed inverse&nbsp;associations of serum 25(OH)D and risks for various infectious illnesses (both rated B).&nbsp;(“Inverse association” refers to an association between lower serum 25(OH)D&nbsp;concentrations and a higher risk for the outcome of interest; “association” or “positive&nbsp;association” refers to an association between higher serum 25(OH)D concentration and a&nbsp;higher risk for the outcome.) A study of healthy U.S. adults found an association between&nbsp;serum concentrations of 25(OH)D levels of 95 nmol/L or higher and reduced risk for acute&nbsp;respiratory viral infections (rated B). One study of adults observed an inverse association&nbsp;of serum 25(OH)D with risk for respiratory disease mortality, and another observed an&nbsp;inverse association with risk for pneumonia (both rated B).</span></p><p><span class=font8 style=font-weight:700>The report identified one new RCT that found no effect of prenatal vitamin D supplementation on the risk for wheeze, atopy, and eczema (rated A). The report also&nbsp;identified five new prospective cohort/nested case-control studies that reported mixed&nbsp;associations of serum concentrations of 25(OH)D and risk for asthma, atopy, and/or&nbsp;eczema. An Australian study observed a significant association of cord blood 25(OH)D and&nbsp;risk for eczema but not allergies at 12 months of age. A prospective cohort study conducted&nbsp;in the United Kingdom found no association between maternal serum 25(OH)D at 34 weeks&nbsp;gestation and asthma, wheeze, and atopy in their children at 6 years of age. A prospective&nbsp;cohort study conducted in the Netherlands found that serum 25(OH)D concentrations at 4&nbsp;years of age significantly predicted asthma and severe asthma at 8 years of age. Another&nbsp;United Kingdom longitudinal study found a small but statistically significant association of&nbsp;wheeze and antecubital dermatitis in 10-year old children with serum levels of 25(OH)D<sub>2&nbsp;</sub>but a negative association with 25(OH)D3. Finally, the HUNT study, a large population&nbsp;health survey in Norway, found no association of vitamin D with asthma in women and&nbsp;only a weak association in men that disappeared when adjusted for confounders.</span></p><p><span class=font8 style=font-weight:700>The current report identified one new RCT and four new prospective cohort studies on the risk for autoimmune disease. A substudy of the Women’s Health Initiative (WHI)&nbsp;calcium/vitamin D (CaD) trial found no effect of supplementation on women’s risk for&nbsp;rheumatoid arthritis (rated A). Two nested case-control studies and one cohort study&nbsp;assessed the association between maternal serum 25(OH)D concentrations or subsequent&nbsp;childhood or adult concentrations with risk for type 1 diabetes mellitus and reported mixed&nbsp;findings (one each rated A, B, and C). One study assessed the effects of maternal serum&nbsp;25(OH)D concentrations on the risk for multiple sclerosis (MS) in the offspring and also&nbsp;assessed the effect of serum 25(OH)D concentrations across the adult population on the&nbsp;risk for subsequent MS and found mixed effects (rated B).</span></p><p><span class=font8 style=font-weight:700>For the original report</span><span class=font8>, two C-rated cohort studies, but no RCTs, evaluated immunologic outcomes. NHANES III found no significant association between serum 25(OH)D&nbsp;concentrations and infectious disease mortality. Another cohort study suggested a possible&nbsp;relationship between higher maternal 25(OH)D concentration (>50 nmol/L) and increased risk of&nbsp;eczema in their children, but the analysis did not control for important confounders, and the&nbsp;25(OH)D concentrations in the children were not measured.</span></p><h3><a name=bookmark65></a><span class=font3 style=font-weight:700>Vitamin D and Pregnancy-Related Outcomes</span></h3><h4><a name=bookmark216></a><span class=font9 style=font-weight:700>Preeclampsia</span></h4><p><span class=font8 style=font-weight:700>For the current report, we identified one article that reported on two combined RCTs assessing the effect of supplemental vitamin D on the risk for preeclampsia:&nbsp;Supplementation with 4,000 IU per day decreased the risk for preeclampsia. We also&nbsp;identified five new nested case-control studies and two prospective cohort studies (all rated&nbsp;B), of which three of the nested case-control studies and the two prospective case-control&nbsp;studies observed an association between 25(OH)D concentrations less than 50 nmol/L and&nbsp;preeclampsia or severe preeclampsia. The other two nested case-control studies (the&nbsp;Canadian EMMA study and a U.S. study) observed no association between low first&nbsp;trimester maternal 25(OH)D levels and severe preeclampsia.</span></p><p><span class=font8 style=font-weight:700>In the original report, </span><span class=font8>one B-rated nested case-cohort study found an association between low 25(OH)D concentration (&lt;37.5 nmol/L) early in pregnancy and preeclampsia.</span></p><p><span class=font9 style=font-weight:700>Other Outcomes</span></p><p><span class=font8 style=font-weight:700>In the current report, we identified two new cohort studies that assessed the association between maternal serum 25(OH)D concentrations and the risk for giving birth to a small-for-gestational-age (SGA) infant and one new nested case-control study and one&nbsp;prospective cohort study that assessed the association with preterm birth. One of the two&nbsp;cohort studies found an increase in the incidence of SGA at the lowest concentration range&nbsp;of maternal serum 25(OH)D compared with higher serum vitamin D concentrations for&nbsp;both white and black mothers (study rated B). The other cohort study, which assessed 412&nbsp;mother-infant pairs, found a U-shaped association between serum 25(OH)D and incidence&nbsp;of SGA among white mothers. The lowest risk was observed from 60 to 80 nmol/L;&nbsp;compared with serum 25(OH)D 37.5-75 nmol/L, SGA odds ratios (95% CI) for levels, 37.5&nbsp;and 0.75 nmol/L were 7.5 (1.8, 31.9) and 2.1 (1.2, 3.8); this association was not seen among&nbsp;black mothers (study rated A).</span></p><p><span class=font8 style=font-weight:700>The nested case-control study that assessed the association with preterm birth found no significant association (rated B), whereas the prospective cohort study did observe an&nbsp;association between lower prenatal serum 25(OH)D concentrations and the risk for&nbsp;preterm birth among women carrying twins (rated A).</span></p><p><span class=font8 style=font-weight:700>We found no new studies for the current report on the relationship of maternal serum 25(OH)D and pregnancy hypertension.</span></p><p><span class=font8 style=font-weight:700>The original report </span><span class=font8>did not identify any eligible studies on the relationship of vitamin D and maternal hypertension, preterm birth, or small infant for gestational age.</span></p><h3><a name=bookmark59></a><span class=font3 style=font-weight:700>Vitamin D and Bone Health</span></h3><p><span class=font8>The results reported in this section are based on the Ottawa EPC Evidence Report “Effectiveness and safety of vitamin D in relation to bone health” and on our updated literature&nbsp;review of studies published after its completion.</span></p><p><span class=font9 style=font-weight:700>Rickets</span></p><p><span class=font8 style=font-weight:700>No new studies assessing the association between vitamin D supplementation and the risk for rickets met the inclusion criteria for the current report.</span></p><p><span class=font8 style=font-weight:700>The original report cited the Ottawa EPC report for these outcomes. </span><span class=font8>The Ottawa EPC report concluded that there is “fair” evidence, regardless of the type of assay, for an association&nbsp;between low serum 25(OH)D concentrations and confirmed rickets. According to the report,&nbsp;there is inconsistent evidence regarding the threshold concentration of serum 25(OH)D, above&nbsp;which rickets does not occur.</span></p><p><span class=font8>Our updated search did not identify new studies examining the association between vitamin D and rickets.</span></p><h4><a name=bookmark217></a><span class=font9 style=font-weight:700>Fractures, Falls, or Performance Measures of Strength</span></h4><p><span class=font8 style=font-weight:700>The current report did not identify any new RCTs that assessed the effect of interventions of vitamin D alone on fracture risk. We identified two new RCTs that&nbsp;examined the effect of supplementation with vitamin D on the risk for falls, two new RCTs&nbsp;on muscle strength, and six new observational studies that assessed the association between&nbsp;serum 25(OH)D and fracture risk; results were inconsistent among them.</span></p><p><span class=font8 style=font-weight:700>Two RCTs were identified for the current report that examined the effects of vitamin D supplementation on the risk for falls among older adults (both rated A). One trial found a&nbsp;small effect, and one found reductions only in particular groups of fallers.</span></p><p><span class=font8 style=font-weight:700>Two RCTs were identified for the current report that examined the effects of 1 year of vitamin D supplementation on muscle strength (both rated A). One RCT showed positive&nbsp;effects among older adults, and one study showed effects only among the participants with&nbsp;lower serum 25(OH) D concentrations at baseline.</span></p><p><span class=font8 style=font-weight:700>Four prospective cohort studies assessed the association between serum 25(OH)D concentrations and muscle strength, and one prospective cohort study assessed the&nbsp;association between serum 2(OH)D and falls. Three of the four prospective cohort studies&nbsp;reported associations between lower serum 25(OH)D and decreased or decreasing muscle&nbsp;strength and performance (one rated A, one rated B, one rated C); a fourth cohort study&nbsp;saw no association with faster rate of decline in muscle function (rated B). An association&nbsp;was seen between lower 25(OH)D concentrations and increased risk for falls over a year&nbsp;(study rated B).</span></p><p><span class=font8 style=font-weight:700>We identified eight prospective cohort and nested case-control studies that assessed the association between 25(OH)D status and fracture risk. Three studies that assessed risk for&nbsp;hip fracture at 6 to 11 years followup (one rated A and two rated B) had mixed results.</span></p><p><span class=font8 style=font-weight:700>Two large-scale studies with B ratings, one among older men and one among older adults of both sexes, found no association of serum 25(OH)D concentration and risk for&nbsp;nonvertebral fracture. Followups to two other large-scale studies, both with A ratings,&nbsp;reported serum 25(OH)D to be a significant predictor of hip fracture and other major&nbsp;osteoporotic fractures in older adults.</span></p><p><span class=font8 style=font-weight:700>Two studies that assessed total fragility fracture (one rated A and one rated B), both in postmenopausal women, also reported inconsistent results.</span></p><p><span class=font8 style=font-weight:700>As described in the original report, </span><span class=font8>the Ottawa EPC report concluded that the associations between serum 25(OH)D concentrations and risk of fractures, falls, and performance measures of&nbsp;strength among postmenopausal women or elderly men are inconsistent.</span></p><p><span class=font8>Findings from three additional C-rated RCTs reported no significant effects of vitamin D supplementation (dosage range 400-822 IU/d) in reducing the risk of total fractures or falls in&nbsp;adults older than 70 years.</span></p><h4><a name=bookmark69></a><span class=font9 style=font-weight:700>Bone Mineral Density or Bone Mineral Content</span></h4><p><span class=font8 style=font-weight:700>To assess the effect of vitamin D on bone mineral content or density, we included only RCTs. Eight new RCTs identified for the current report assessed the effects of&nbsp;supplemental vitamin D alone on bone mineral content (BMC) or density (BMD). One of&nbsp;the eight, a study in infants (rated A), showed a trend toward increasing BMC. A second&nbsp;study, in postmenopausal women, found that 1,000 IU vitamin D per day reduced loss of&nbsp;BMD at the hip compared with no or 400 IU per day supplementation, but no effect was&nbsp;seen on spinal BMD (study rated A). Six RCTs, two in teen girls and the remaining four in&nbsp;adults of both sexes (one rated A, four rated B, and one rated C) showed no effect of&nbsp;vitamin D supplementation for as much as 2 years on BMD.</span></p><p><span class=font8 style=font-weight:700>As described in the original report</span><span class=font8>, the Ottawa EPC report concluded that observational studies suggested a correlation between higher serum 25(OH)D concentrations and larger values&nbsp;of BMC indices for older children and adolescents (6 months through 18 years old). In addition,&nbsp;there was “fair” evidence among observational studies of postmenopausal women and elderly&nbsp;men to support an association between higher serum 25(OH)D and higher BMD or increases in&nbsp;BMD at the femoral neck. However, there was discordance between the results from RCTs and&nbsp;the majority of observational studies.</span></p><p><span class=font8>For this outcome, we included only RCTs for our update literature review. Consistent with the findings of RCTs in the Ottawa EPC report, the three additional RCTs (one rated A, one B,&nbsp;one C) showed no significant effects of vitamin D supplementation on BMC in children or BMD&nbsp;in adults.</span></p><h3><a name=bookmark67></a><span class=font3 style=font-weight:700>Vitamin D and All-Cause Mortality</span></h3><p><span class=font8 style=font-weight:700>No new RCTs were identified for the current report that assessed the effect of vitamin D supplementation on risk for all-cause mortality. The current report identified 25 new&nbsp;articles that assessed the association between serum 25(OH)D concentration and risk for&nbsp;all-cause mortality. Of the 25, 7 found no association (1 rated A, 6 rated B), 16 found an&nbsp;association of lower serum 25(OH)D concentrations with increased risk for mortality (6&nbsp;rated A, 9 rated B: 1 article reported on 2 studies), and 2 reported an association of both&nbsp;higher and lower 25(OH)D concentrations with increased mortality risk (rated A and B).</span></p><p><span class=font8 style=font-weight:700>The assessment of the literature on vitamin D and all-cause mortality in the original report was based on a reanalysis of a</span><span class=font8>n existing systematic review and metaanalysis of RCTs&nbsp;on vitamin D supplementation for mortality. One additional C-rated RCT was identified. Four&nbsp;additional cohort studies (one rated B, three C) on the association of vitamin D and all-cause&nbsp;mortality also qualified. Four RCTs (N=13,899) were included in the reanalysis of the systematic&nbsp;review. In each study, mean age was older than70 years and dosages ranged between 400 to 880&nbsp;IU per day. Vitamin D supplementation had no significant effect on all-cause mortality&nbsp;(summary relative risk [RR]=0.97, 95% CI 0.92, 1.02; random effects model). There is little&nbsp;evidence for between-study heterogeneity in these analyses. Three of the cohort studies found no&nbsp;significant association between 25(OH)D concentrations and all-cause mortality, but one found a&nbsp;significant trend for lower odds of death with increasing 25(OH)D concentrations, greater than&nbsp;23 nmol/L in men and greater than 19 nmol/L in women.</span></p><h3><a name=bookmark68></a><span class=font3 style=font-weight:700>Vitamin D and Hypertension and Blood Pressure</span></h3><h4><a name=bookmark218></a><span class=font9 style=font-weight:700>Hypertension</span></h4><p><span class=font8 style=font-weight:700>For the current report we identified no new RCTs that addressed the relationship of serum 25(OH)D concentrations or supplementation with hypertension. A large prospective&nbsp;cohort study identified for the current report that evaluated the association between serum&nbsp;25(OH)D concentration and the risk for hypertension using the Intermountain database&nbsp;found a highly significant association of very low and low baseline serum 25(OH)D&nbsp;concentrations and the prevalence of hypertension at an average of 1.3 years followup&nbsp;(rated C). The Intermountain data were analyzed with 25(OH)D cutoff points of 37.5 and&nbsp;75 nmol/L. Significant associations were identified for those with serum concentrations&nbsp;below 75 nmol/L. An assessment of the association between serum 25(OH)D and incident&nbsp;hypertension in 1,211 participants in the Physicians’ Health Study (men of average age&nbsp;57.6) at a mean followup of 15.3 years (maximum 27 years) showed a marginally significant&nbsp;j-shaped association, with men in the lowest two quartiles and in the highest quartile at&nbsp;higher risk for incident hypertension than those in the third quartile (rated A).</span></p><p><span class=font8 style=font-weight:700>The original report </span><span class=font8>identified no relevant RCTs. In a B-rated combined analysis of the Health Professionals Followup Study and the Nurses’ Health Study, significantly higher&nbsp;incidence of hypertension at 4 years was found in men and women (mostly within the 51 to 70&nbsp;year old life stage) with serum 25(OH)D concentrations less than 37.5 nmol/L, compared with&nbsp;those with higher 25(OH)D concentrations. At 8 years, a similar significant association was&nbsp;found for men but not for women.</span></p><h4><a name=bookmark219></a><span class=font9 style=font-weight:700>Blood Pressure</span></h4><p><span class=font8 style=font-weight:700>The current study identified 10 new RCTs that assessed the effects of 1 or more dosage levels of vitamin D compared with placebo on blood pressure in adults. Dosages ranged&nbsp;from 125 IU to 5700 IU per day. Followup ranged from 3 months to 1 year. Participants&nbsp;included postmenopausal women; middle-aged U.S. blacks (rated A); overweight young&nbsp;Chinese and Dutch adults; healthy South Asian women residing in the United Kingdom;&nbsp;and healthy young women from Spain. Of the 10 RCTs, no effect of vitamin D&nbsp;supplementation was observed in 7 (5 rated A and 2 rated B); vitamin D significantly&nbsp;decreased systolic blood pressure in 2 studies (both systolic and diastolic in one of the&nbsp;studies) (rated B); and in the final study, systolic blood pressure actually increased slightly&nbsp;in the supplemented group (rated C).</span></p><p><span class=font8>The original report evaluated only RCTs for changes in blood pressure. Three RCTs of vitamin D versus placebo (one rated A, two B) evaluated blood pressure outcomes. The trials&nbsp;used a range of vitamin D dosages (800 IU/d to 120,000 IU every 2 weeks), with or without&nbsp;supplemental calcium in both groups. All trials reported no significant effect on diastolic blood&nbsp;pressure, but the effect upon systolic blood pressure was inconsistent. The three trials found&nbsp;either a net reduction, no change, or a net increase in systolic blood pressure with vitamin D&nbsp;supplementation after 5-8 weeks.</span></p><h3><a name=bookmark220></a><span class=font10 style=font-weight:700>Combined Vitamin D and Calcium </span><span class=font3 style=font-weight:700>Combined Vitamin D and Calcium and Growth</span></h3><p><span class=font8 style=font-weight:700>The current report did not consider growth as an outcome, except for prenatal growth. No new studies were identified. In the original report, </span><span class=font8>one C-rated nonrandomized study from&nbsp;India compared combined vitamin D (1200 IU/d) and calcium (375 mg/d) to no supplementation&nbsp;in women in their third trimester of pregnancy. Infants of women who received supplementation&nbsp;were significantly heavier at birth.</span></p><h3><a name=bookmark70></a><span class=font3 style=font-weight:700>Combined Vitamin D and Calcium and Cardiovascular Events</span></h3><p><span class=font8 style=font-weight:700>For the original study</span><span class=font8>, a variety of cardiovascular events after 7 years were evaluated in the WHI trial of combined vitamin D (400 IU/d) and calcium carbonate (1000 mg/d) (CaD) versus&nbsp;placebo in postmenopausal women. This study was rated B. No significant effect was found with&nbsp;combined vitamin D and calcium supplementation on any cardiovascular outcome. However,&nbsp;borderline nonsignificant associations were found for three outcomes, suggesting increased risk&nbsp;with supplementation for a composite cardiac outcome, invasive cardiac interventions, and&nbsp;transient ischemic attacks. No significant associations were found for a composite cardiac&nbsp;outcome, coronary heart disease death, myocardial infarction, hospitalization for heart failure,&nbsp;angina, stroke or transient ischemic attack, and stroke alone.</span></p><p><span class=font8 style=font-weight:700>The current report identified only one new study that assessed the effects of vitamin D and calcium supplements combined on cardiovascular events: A post hoc analysis of the&nbsp;WHI CaD trial that stratified participants on the basis of personal supplement use before&nbsp;and during the trial found no impact of the study supplements alone (either positive or&nbsp;negative) on risk for cardiovascular events (rated A).</span></p><h3><a name=bookmark71></a><span class=font3 style=font-weight:700>Combined Vitamin D and Calcium and Body Weight</span></h3><p><span class=font8 style=font-weight:700>This outcome was not investigated for the current report.</span></p><p><span class=font8 style=font-weight:700>For the original report, n</span><span class=font8>o studies evaluated the risk of obesity or overweight. Only RCTs were evaluated for changes in body weight. Two RCTs (rated B and C) were identified that&nbsp;evaluated the effects of combined vitamin D and calcium supplementation on body weight in the&nbsp;setting of either an energy neutral diet or an energy restricted diet. Both used vitamin D 400 IU&nbsp;per day and calcium carbonate (1,000 mg/d or 1,200 mg/d) and were restricted to women. The B-rated WHI trial, after 7 years, found a highly significant (P=0.001), but clinically questionable&nbsp;net difference of -0.13 kg between the supplemented and placebo groups. In a small C-rated trial,&nbsp;after 15 weeks, those overweight women on supplement lost 4 kg and those on placebo lost 3 kg.&nbsp;This difference was not statistically significant.</span></p><h3><a name=bookmark72></a><span class=font3 style=font-weight:700>Combined Vitamin D and Calcium and Cancer</span></h3><h4><a name=bookmark221></a><span class=font9 style=font-weight:700>Total Cancer</span></h4><p><span class=font8 style=font-weight:700>No new studies were identified for the current report on the association of combined vitamin D and calcium intake with any cancer outcomes. However, as described below,&nbsp;data from the WHI calcium and vitamin D (CaD) trial were reanalyzed.</span></p><p><span class=font8>Two RCTs (rated B and C) </span><span class=font8 style=font-weight:700>identified for the original report </span><span class=font8>reported effects of combined vitamin D and calcium supplementation on the risk of total cancer. The RCTs reported&nbsp;inconsistent results. The B-rated WHI trial (vitamin D 400 IU/d and calcium 1,000 mg/d)&nbsp;showed no effects while the B-rated trial (vitamin D 1,000 IU/d and calcium 1,400-1,500 mg/d)&nbsp;reported a significant reduction of total cancer risk. However, baseline serum 25(OH)D&nbsp;concentrations were substantially different between these two trials (42 nmol/L [WHI] versus 72&nbsp;nmol/L).</span></p><h4><a name=bookmark222></a><span class=font9 style=font-weight:700>Colorectal Cancer</span></h4><p><span class=font8>Only the B-rated WHI trial </span><span class=font8 style=font-weight:700>identified for the original report </span><span class=font8>evaluated colorectal cancer. It reported no significant reduction in colorectal cancer incidence or mortality with combined&nbsp;vitamin D (400 IU/d) and calcium carbonate (1,000 mg/d) compared with placebo. </span><span class=font8 style=font-weight:700>A post hoc&nbsp;analysis of the WHI CaD trial identified for the current report that stratified participants&nbsp;by baseline use of personal vitamin D and calcium supplements found no difference in risk&nbsp;for colorectal cancer by previous or additional supplement use.</span></p><h4><a name=bookmark223></a><span class=font9 style=font-weight:700>Colorectal Polyps</span></h4><p><span class=font8>The B-rated WHI trial </span><span class=font8 style=font-weight:700>identified for the original report </span><span class=font8>was the only trial of combined vitamin D<sub>3</sub> and calcium supplements to evaluate colorectal polyps. It found no significant effect&nbsp;of supplementation on colorectal polyp incidence. A B-rated subgroup analysis of a secondary&nbsp;prevention trial of adenomatous adenoma reported that people taking calcium supplements (1200&nbsp;mg/d) who had higher baseline serum 25(OH)D concentrations (>72.6 nmol/L) had significantly&nbsp;lower risk of relapse compared with placebo. In contrast, among people with lower baseline&nbsp;serum 25(OH)D concentrations, there was no significant difference in relapse rates between&nbsp;those taking calcium supplements or placebo (P=0.01 for interaction between calcium&nbsp;supplementation and 25(OH)D concentration).</span></p><h4><a name=bookmark224></a><span class=font9 style=font-weight:700>Breast Cancer</span></h4><p><span class=font8>Only the B-rated WHI trial evaluated breast cancer. It reported no significant reduction in breast cancer incidence or mortality with combined vitamin D (400 IU/d) and calcium carbonate&nbsp;(1000 mg/d) compared with placebo. </span><span class=font8 style=font-weight:700>A post hoc analysis of the WHI CaD trial identified for&nbsp;the current report that stratified participants by baseline use of personal vitamin D and&nbsp;calcium supplements found a trend toward a reduction in risk for breast cancer among&nbsp;women in the intervention group who had not been using personal supplements at baseline.</span></p><h3><a name=bookmark225></a><span class=font3 style=font-weight:700>Combined Vitamin D and Calcium and Preeclampsia, Hypertension in Pregnancy, and Preterm Birth or Small Infant for Gestational Age</span></h3><h4><a name=bookmark226></a><span class=font9 style=font-weight:700>Preeclampsia</span></h4><p><span class=font8 style=font-weight:700>No new studies were identified for the current report that assessed this outcome. In the original report, </span><span class=font8>one C-rated RCT found no significant effect of combined vitamin D (1200&nbsp;IU/d) and calcium (375 mg/d) supplementation on prevention of preeclampsia.</span></p><h4><a name=bookmark26></a><span class=font9 style=font-weight:700>Other Outcomes</span></h4><p><span class=font8>No studies evaluated the relationship of vitamin D with or without calcium and pregnancy-related high blood pressure, preterm birth, or small infant for gestational age.</span></p><h3><a name=bookmark73></a><span class=font3 style=font-weight:700>Combined Vitamin D and Calcium and Bone Health</span></h3><p><span class=font8>The results reported in this section are based on the Ottawa EPC Evidence Report “Effectiveness and Safety of Vitamin D in Relation to Bone Health” and on our updated&nbsp;literature review of studies published after its completion.</span></p><h4><a name=bookmark227></a><span class=font9 style=font-weight:700>Rickets, Fractures, Falls, or Performance Measures</span></h4><p><span class=font8 style=font-weight:700>For the current report, we identified no new studies on the effect of vitamin D and calcium supplementation on rickets that met the inclusion criteria.</span></p><p><span class=font8 style=font-weight:700>The current report identified one new RCT and one reanalysis of the WHI CaD trial that examined the effect of an intervention with vitamin D and calcium on osteoporotic&nbsp;fracture risk among postmenopausal women. The reanalysis of data from the WHI CaD&nbsp;trial compared the effects of the intervention between women who had been using personal&nbsp;vitamin D and/or calcium supplements at baseline. The primary outcome was risk for hip&nbsp;fracture at 5 or more years and secondary outcomes included other fractures. The&nbsp;reanalysis found that among women who were not taking calcium or vitamin D&nbsp;supplements at baseline, the risk for hip fracture was significantly decreased (no effect was&nbsp;seen among women who had been taking supplements); it found no effect of the&nbsp;intervention on overall fracture risk in women who had been taking supplements or in&nbsp;those who had not (rated A).<sup>2</sup> The second RCT, the OSTPRE study, found no effect of 3&nbsp;years’ supplementation with calcium and vitamin D on risk for total, nonvertebral, distal&nbsp;forearm, upper extremity, or lower extremity fragility fractures among 3,195&nbsp;postmenopausal women age 65 to 71 years (rated A).</span></p><p><span class=font8 style=font-weight:700>One RCT on middle-age and older Australian men (age 50 to 79) tested the effect of an 18-month intervention of daily vitamin D (800 IU) and calcium (1,000 mg) on measures of&nbsp;muscle function (rated A). No effect was seen on any measure of muscle function, including&nbsp;step test, gait speed, or sway.</span></p><p><span class=font8 style=font-weight:700>We identified one new RCT that assessed effects of supplementation on risk for falling: This study found no effect of the intervention (study rated C).</span></p><p><span class=font8 style=font-weight:700>As described in the original report, </span><span class=font8>the Ottawa EPC report concluded that supplementation with vitamin D (most studies used D<sub>3</sub>) plus calcium is effective in reducing fractures in&nbsp;institutionalized populations, but evidence that supplemental vitamin D reduces falls in&nbsp;postmenopausal women and older men is inconsistent.</span></p><p><span class=font8>One study published after the Ottawa EPC report analyzed the performance measure outcomes in a small sample of postmenopausal women from the WHI trial. After 5 years, the&nbsp;study found generally no differences in performance measures between the groups taking&nbsp;vitamin D (400 IU/d) plus calcium (1,000 mg/d) supplementation or placebo. One RCT of&nbsp;premenopausal women (aged 17-35 years) found that vitamin D (800 IU/d) in combination with&nbsp;calcium (2,000 mg/d) supplementation reduced the risk of stress fracture from military training&nbsp;compared with placebo.</span></p><h4><a name=bookmark228></a><span class=font9 style=font-weight:700>Bone Mineral Density or Bone Mineral Content</span></h4><p><span class=font8 style=font-weight:700>Of the seven new RCTs identified for this report on the effect of vitamin D and calcium supplementation on bone density or content, two studies were in girls (rated B) or young&nbsp;women (rated A): Both showed positive effects on BMC and BMD, respectively. Four of the&nbsp;RCTs enrolled postmenopausal women (one rated A, two rated B, and one rated C): All&nbsp;showed some positive effects, but the effects differed across the studies in the areas that&nbsp;were positively affected. One intervention that enrolled men showed no effects (rated A).&nbsp;Followup times ranged from 1 to 6 years. Vitamin D supplementation ranged from 200 to&nbsp;800 IU per day, with calcium ranging from 600 to 1200 mg per day.</span></p><p><span class=font8 style=font-weight:700>As described in the original report</span><span class=font8>, the Ottawa EPC report concluded that overall, there is good evidence that combined vitamin D</span><span class=font6>3</span><span class=font8> and calcium supplementation resulted in small&nbsp;increases in BMD of the spine, total body, femoral neck, and total hip. In RCTs among&nbsp;(predominantly) postmenopausal women, vitamin D<sub>3</sub> (&lt;800 IU/d) plus calcium (500 mg/d)&nbsp;supplementation resulted in small increases in BMD of the spine, the total body, femoral neck&nbsp;and total hip.</span></p><p><span class=font8>For this outcome, only RCTs were included for the update literature review. Three new RCTs (two rated B, one C) were identified that evaluated BMD outcomes. Two of the trials showed&nbsp;significant improvement in BMD in postmenopausal women receiving vitamin D<sub>2</sub> (300 IU/d) or&nbsp;D<sub>3</sub> (1,200 IU/d) plus calcium (1,200 mg/d) compared with placebo.</span></p><p><span class=font8>One C-rated RCT evaluated BMC outcomes in healthy girls (aged 10-12 years). Compared with placebo, there was no significant effect of supplementation with vitamin D<sub>3</sub> (200 IU/d) plus&nbsp;calcium (1,000 mg/d) on BMC changes.</span></p><h3><a name=bookmark74></a><span class=font3 style=font-weight:700>Combined Vitamin D and Calcium and All-Cause Mortality</span></h3><p><span class=font8 style=font-weight:700>No new studies were identified for the current report that addressed this question. For the original report, </span><span class=font8>an existing systematic review and metaanalysis of 18 RCTs on vitamin D&nbsp;supplementation for mortality was reanalyzed. No additional RCTs were identified. Eleven&nbsp;RCTs (N=44,688) of combined vitamin D (300-800 IU/d) and calcium (500-1,200 mg/d)&nbsp;supplementation met inclusion criteria for our reanalysis. The metaanalysis found no significant&nbsp;relationship between combined supplementation of vitamin D and calcium and all-cause&nbsp;mortality (RR=0.93, 95% CI 0.86, 1.01; random effects model). There is little evidence for&nbsp;between-study heterogeneity in these analyses. Among eight RCTs (N=44,281) in&nbsp;postmenopausal women, there was no significant effect of supplementation on all-cause&nbsp;mortality.</span></p><h3><a name=bookmark78></a><span class=font3 style=font-weight:700>Combined Vitamin D and Calcium and Hypertension and Blood Pressure</span></h3><p><span class=font8 style=font-weight:700>No new studies were identified for the current report that addressed this question. For the original report, </span><span class=font8>only the B-rated WHI trial evaluated the risk of developing hypertension.&nbsp;Among the subset of women without hypertension at baseline, at 7 years the trial found the&nbsp;combined supplementation had no effect on incident hypertension. Only RCTs were evaluated&nbsp;for changes in blood pressure. Two trials (one rated B, one C) tested combined vitamin D (400&nbsp;IU/d) and calcium (1,000 or 1,200 mg/d) and blood pressure. Both found no significant effect of&nbsp;supplementation on blood pressure after 15 weeks or 6.1 years.</span></p><h3><a name=bookmark229></a><span class=font10 style=font-weight:700>How Does Dietary Intake of Vitamin D From Fortified Foods and Vitamin D Supplementation Affect Serum 25(OH)D Concentrations&nbsp;(Arrow 4)?</span></h3><p><span class=font8>The results reported in this section are based on the Ottawa EPC Evidence Report “Effectiveness and safety of vitamin D in relation to bone health,” on our updated literature&nbsp;review of studies published after its completion, </span><span class=font8 style=font-weight:700>on new studies identified for the current&nbsp;report, and on a high-quality systematic review published since the original report</span><span class=font8>.</span></p><p><span class=font8 style=font-weight:700>The current report identified 1 new existing systematic review published since the original report that addressed the question as well as 18 new RCTs that met the inclusion&nbsp;criteria (2 that used fortified foods and the remainder that used supplements). The&nbsp;systematic review, based on 76 RCTs, reported widely varying increases in serum&nbsp;concentrations of 25(OH) for similar doses of vitamin D, with a general increase in serum&nbsp;concentration with supplement administration. Of the RCTs identified for the current&nbsp;report that met the criteria for inclusion in an assessment of dose response, all reported&nbsp;increases in serum 25(OH)D with supplementation; however, the findings varied by age&nbsp;group and health status of participants, baseline serum 25(OH)D concentration, dose,&nbsp;duration, and assay used to assess serum 25(OH)D. Only one study used the National&nbsp;Institute of Standards and Technology vitamin D as a reference standard, and six reported</span></p><p><span class=font8 style=font-weight:700>participating in the Vitamin D External Quality Assessment Scheme. Of 54 RCTs included in the original and the current report, only 4 reported the year the assays were conducted.</span></p><p><span class=font8 style=font-weight:700>As described in the original report</span><span class=font8>, the Ottawa EPC report concluded that there is “good” evidence that dietary intake of vitamin D increases serum 25(OH)D concentrations among&nbsp;adults. Our updated search did not identify new RCTs on dietary intakes of vitamin D from&nbsp;fortified foods.</span></p><p><span class=font8>We graphically evaluated the net changes in serum 25(OH)D concentration against the doses of vitamin D supplementation using data from 26 RCTs with 28 comparisons in adults. Only&nbsp;RCTs of daily vitamin D<sub>3</sub> supplementation (doses ranged from 200 to 5000 IU/d) alone or in&nbsp;combination with calcium supplementation (doses ranged from 500 to 1550 mg/d) that provided&nbsp;sufficient data for the calculations were included. The relationship between increasing doses of&nbsp;vitamin D<sub>3</sub> with increasing net change in 25(OH)D concentration was evident in both adults and&nbsp;children. It was also apparent that the dose-response relationships differ depending on study&nbsp;participants’ serum 25(OH)D concentrations (&lt;40 vs. >40 nmol/L) at baseline, and depending on&nbsp;duration of supplementation (&lt;3 vs. >3 months).</span></p><h3><a name=bookmark82></a><span class=font10 style=font-weight:700>Stratification of Key Outcomes by Vitamin D Assay Method</span></h3><p><span class=font8 style=font-weight:700>In addition to plotting the data for Vitamin D dose-response by the method used to assay serum 25(OH)D (Figure 15), for all outcomes reported in three or more RCTs or&nbsp;seven or more observational studies, we stratified the studies according to the assay method&nbsp;used to assess serum 25(OH)D concentrations (radioimmunoassay, radioreceptor/ligand&nbsp;assay, enzyme-linked immunoadsorption assay, chemiluminescence assay, and HPLC-tandem<sup>a</sup> mass spectrometry). These stratified tables appear in Appendix H of the full&nbsp;report.</span></p><h3><a name=bookmark83></a><span class=font10 style=font-weight:700>Outcomes for Tolerable Upper Intake Levels</span></h3><p><span class=font8>We included only clinical outcomes of tolerable upper intake levels, such as all-cause mortality, cancer (incidence and mortality), soft tissue calcification, renal outcomes, and adverse&nbsp;events reported in RCTs. Results of all-cause mortality and cancer have been described in&nbsp;previous sections.</span></p><h3><a name=bookmark24></a><span class=font3 style=font-weight:700>Renal Outcomes</span></h3><p><span class=font8 style=font-weight:700>As described in the original report</span><span class=font8>, the WHI trial (vitamin D3 400 IU in combination with</span></p><p><span class=font8>1,000 mg calcium carbonate vs. placebo) found an increase in the risk of renal stones. No other&nbsp;study was identified that evaluated the effect of vitamin D, calcium, or combined vitamin D and&nbsp;calcium on other renal outcomes.</span></p><p><span class=font8 style=font-weight:700>For the current report, two new studies assessed the occurrence of nephrolithiasis among participants in RCTs that administered approximately 1,100 and 2,000 IU per day&nbsp;supplemental vitamin D without calcium. No incidents of nephrolithiasis were reported in&nbsp;either study.</span></p><p><span class=font8><sup>a</sup> HPLC is high pressure liquid chromatography.</span></p><h3><a name=bookmark85></a><span class=font3 style=font-weight:700>Adverse Events Reported in RCTs</span></h3><p><span class=font8>The </span><span class=font8 style=font-weight:700>original report noted that </span><span class=font8>reporting of adverse events in RCTs was generally inadequate, and most trials were not adequately powered to detect adverse events. Among the 63&nbsp;RCTs included in the original report, 47 did not report information on adverse events.</span></p><p><span class=font8 style=font-weight:700>Among 18 new RCTs included in the current study, most did not include any information on adverse events. One study, which administered 2000 or 4000 IU per day to&nbsp;women during the third trimester of pregnancy reported no adverse events. Three studies&nbsp;reported on only one specific outcome, hypercalcemia/serum calcium, or reported on this&nbsp;outcome and stated that no other adverse events were reported. Supplementation ranged&nbsp;from 400 to 5000 IU per day in these studies; only 1 case of hypercalcemia was reported&nbsp;across all 4 of the studies, in a trial that administered 1000 IU per day plus 1000 mg&nbsp;calcium. Five other studies that assessed hypercalcemia also reported no cases.</span></p><p><span class=font8 style=font-weight:700>Five new studies reported on gastrointestinal symptoms, of which only one included supplemental calcium. Two new studies reported on serious adverse events, including one&nbsp;death, cancer diagnoses, and acute surgeries, which were more prevalent in the placebo&nbsp;group and thus could not have been related to the use of vitamin D.</span></p><p><span class=font8 style=font-weight:700>In the original report, </span><span class=font8>5 RCTs (in 6 publications) that enrolled a total of 444 subjects reported no adverse events during the trial periods. Eleven RCTs reported at least one adverse&nbsp;event. Excessive gas, bloating, and gastrointestinal discomforts were reported to be associated&nbsp;with calcium supplementation (doses ranged from 600 to 1000 mg/d). Other RCTs of vitamin D&nbsp;(doses ranged from 400 to 5,714 IU/d vitamin D<sub>3</sub> or ranged from 5000 to 10,000 IU/d vitamin&nbsp;D<sub>2</sub>) and/or calcium supplementations (doses ranged from 200 to 1,500 mg/d) reported few cases&nbsp;of gastrointestinal disruption (such as constipation, diarrhea, or upset stomach), musculoskeletal&nbsp;soreness, primary hyperparathyroidism, hypercalcemia, and renal calculi. However, these&nbsp;adverse events may or may not be associated with vitamin D and/or calcium supplementation in&nbsp;this study.</span></p><h2><a name=bookmark230></a><span class=font4 style=font-weight:700>Summation</span></h2><p><span class=font8>The </span><span class=font8 style=font-weight:700>original </span><span class=font8>systematic review identified 165 primary study articles and 11 systematic reviews (which incorporated over 200 additional primary articles) that met the eligibility criteria&nbsp;established by the Technical Expert Panel. </span><span class=font8 style=font-weight:700>The current study identified 154 new articles&nbsp;(reporting 156 studies) and two systematic reviews that met the eligibility criteria. </span><span class=font8>Despite&nbsp;the relatively large number of studies included, with the following few exceptions, it is difficult&nbsp;to make any substantive statements on the basis of the available evidence concerning the&nbsp;association of either serum 25(OH)D concentration, vitamin D supplementation, calcium intake,&nbsp;or the combination of both nutrients, with the various health outcomes because most of the&nbsp;findings were inconsistent.</span></p><p><span class=font8>In general, </span><span class=font8 style=font-weight:700>the original report found that </span><span class=font8>among RCTs of hypertensive adults, calcium supplementation (400-2,000 mg/d) lowered systolic, but not diastolic, blood pressure by a small&nbsp;but statistically significant amount (2-4 mm Hg). </span><span class=font8 style=font-weight:700>The current report did not address calcium&nbsp;supplementation alone.</span></p><p><span class=font8>For </span><span class=font8 style=font-weight:700>adult </span><span class=font8>body weight, despite a wide range of calcium intakes (from supplements or from dairy and nondairy sources) across the calcium trials, the RCTs </span><span class=font8 style=font-weight:700>identified for the original&nbsp;report </span><span class=font8>were fairly consistent in finding no significant effect of increased calcium intake on body&nbsp;weight. </span><span class=font8 style=font-weight:700>The current report addressed body weight only in infants and did not address the&nbsp;effects of calcium. Effects of vitamin D interventions on birth weight were inconclusive.</span></p><p><span class=font8>For growth, a metaanalysis of 17 RCTs </span><span class=font8 style=font-weight:700>identified for the original report </span><span class=font8>did not find a significant effect on weight and height gain attributable to calcium supplement in children&nbsp;ranged from 3 to 18 years of age. </span><span class=font8 style=font-weight:700>The current report did not address pediatric weight or&nbsp;height gain or the effects of calcium alone.</span></p><p><span class=font8>For </span><span class=font8 style=font-weight:700>intermediate indices of </span><span class=font8>bone health, one well-conducted systematic review of RCTs </span><span class=font8 style=font-weight:700>identified for the original report </span><span class=font8>found that vitamin D<sub>3</sub> (up to 800 IU/d) plus calcium&nbsp;(approximately 500 mg/d) supplementation resulted in small increases in BMD of the spine, total&nbsp;body, femoral neck, and total hip in populations consisting predominantly of women in late&nbsp;menopause. </span><span class=font8 style=font-weight:700>Of the studies identified for the current report, one of seven RCTs of vitamin D&nbsp;supplementation alone and six of seven RCTs of vitamin D plus calcium found increases in&nbsp;BMC/BMD: The study of vitamin D alone that reported a positive effect enrolled infants,&nbsp;whereas the studies of vitamin D and calcium primarily enrolled postmenopausal women;&nbsp;the study that reported no effect of administering both vitamin D and calcium enrolled only&nbsp;men. Thus, the findings from the 2009 report with respect to both vitamin D alone and in&nbsp;combination with calcium relevant to intermediate indices of bone health remain&nbsp;unchanged with the incorporation of newer, relevant data. Findings on clinical outcomes&nbsp;are reported above.</span></p><p><span class=font8 style=font-weight:700>For clinical outcomes of bone health (fracture risk), a post-hoc analysis of the WHI CaD 7-year data that stratified participants by use of personal vitamin D and calcium&nbsp;supplements at baseline found that among women not taking supplements at baseline, the&nbsp;intervention significantly reduced the risk for hip fracture.</span></p><p><span class=font8>For breast cancer, subgroup analyses in four cohort studies </span><span class=font8 style=font-weight:700>identified for the original report </span><span class=font8>consistently found that calcium intake in the range of 780 to 1,750 mg/d in premenopausal&nbsp;women was associated with a decreased risk for breast cancer. In contrast, cohort studies of&nbsp;postmenopausal women are consistent in showing no association of calcium intake with the risk&nbsp;of breast cancer. </span><span class=font8 style=font-weight:700>Studies of calcium alone were not included in the updated report.</span></p><p><span class=font8>For prostate cancer, three of four cohort studies </span><span class=font8 style=font-weight:700>identified for the original report </span><span class=font8>found significant associations between higher calcium intake (>1,500 or >2,000 mg/day) and increased&nbsp;risk of prostate cancer, compared with men consuming lower amount of calcium (500-1,000&nbsp;mg/day). </span><span class=font8 style=font-weight:700>Studies of calcium alone were not included in the updated report.</span></p><p><span class=font8>For cardiovascular events, a cohort study and a nested case-control study </span><span class=font8 style=font-weight:700>identified for the original report </span><span class=font8>found associations between lower serum 25(OH)D concentrations (less than&nbsp;either about 50 or 75 nmol/L) and increased risk of total cardiovascular events; however, a RCT&nbsp;found no effect of supplementation, and studies of specific cardiovascular events were too sparse&nbsp;to reach conclusions. </span><span class=font8 style=font-weight:700>For the current report, studies assessing associations between&nbsp;cardiovascular events and serum 25(OH)D concentrations also reported inconsistent&nbsp;results. Thus, the findings from the 2009 report relative to vitamin D remain unchanged&nbsp;with the incorporation of newer, relevant data. One high-quality systematic review that&nbsp;included some of the studies reviewed in the original report and some in the current report&nbsp;found a significant association between lower serum 25(OH)D concentrations and&nbsp;increased risk for total cardiovascular disease and coronary heart disease risks.</span></p><p><span class=font8>Taken together, six cohort studies of calcium intake suggest that in populations at relatively increased risk of stroke and with relatively low dietary calcium intake (i.e., in East Asia), lower&nbsp;levels of calcium intake under about 700 mg per day are associated with higher risk of stroke.&nbsp;This association, however, was not replicated in Europe or the United States, and one Finnish&nbsp;study found a possible association of increased risk of stroke in men with calcium intakes above</span></p><p><span class=font8>1,000 mg. </span><span class=font8 style=font-weight:700>Again, studies of calcium alone were not included in the current report.</span></p><p><span class=font8>Studies on the association between either serum 25(OH)D concentration or calcium intake and other forms of cancer (colorectal, pancreas, prostate, all-cause); incidence of hypertension or&nbsp;specific cardiovascular disease events; immunologic disorders; and pregnancy-related outcomes&nbsp;including preeclampsia were either few in number or reported inconsistent findings. Too few&nbsp;studies of combined vitamin D and calcium supplementation have been conducted to allow&nbsp;adequate conclusions about its possible effects on health. The WHI trial was commonly the only&nbsp;evidence available for a given outcome.</span></p><p><span class=font8 style=font-weight:700>For the current report, we abstracted the methods used to assay serum 25(OH)D for all RCTs included in the assessment of dose-response, as well as the RCTs included in the&nbsp;original report and plotted dose response according to assay method. Although most&nbsp;studies employed radioimmunoassays, some relied on other immunoassay methods,&nbsp;receptor binding assays, and HPLC/tandem mass spectrometry. To characterize the assay&nbsp;methods more completely, we also noted the country and year in which the assay was&nbsp;performed, when reported, and any information provided on standardization; however,&nbsp;very few studies reported the year assays were conducted or how assays were standardized.&nbsp;Combined with the evidence regarding the significant effect of season of blood draw on&nbsp;serum 25(OH)D concentrations, this lack of information on year of assay renders&nbsp;comparing or combining outcomes challenging, even when the same type of assay was used.</span></p><p><span class=font8 style=font-weight:700>As demonstrated by the findings of a number of trials and post hoc analyses identified for the current report, adherence to interventions in trials also remains a barrier to&nbsp;interpretation of study findings and assessing the true effects of supplementation on health&nbsp;outcomes.</span></p><p><span class=font8>Table A summarizes the findings of the 2009 and current reports by study design and compares the findings across reports. “None identified” indicates that no studies were identified&nbsp;for that outcome and study design. “None included” indicates that studies for that outcome or of&nbsp;that design were excluded from the reports. For observational studies, “inverse association”&nbsp;refers to an association between lower serum 25(OH)D concentrations and a higher risk for the&nbsp;outcome of interest; “association” or “positive association” refers to an association between&nbsp;higher serum 25(OH)D concentration and a higher risk for the outcome.</span></p><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of RCTs)&nbsp;General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of RCTs)&nbsp;General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font1 style=font-weight:700>Bone Health&nbsp;Vitamin D</span></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td></tr><tr><td><p><span class=font0>Rickets</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>None identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>Conclusions based on</span></p><p><span class=font0>2006 Ottawa EPC report showed strong effect</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>No new studies to compare</span></p></td></tr><tr><td><p><span class=font0>BMD/BMC</span></p></td><td><p><span class=font0>(3 RCTs) No effects of vitamin D&nbsp;supplementation on&nbsp;BMC or BMD</span></p></td><td><p><span class=font0>None included</span></p></td><td style=vertical-align:bottom><p><span class=font0>The Ottawa EPC report concluded that&nbsp;observational studies&nbsp;suggested a correlation&nbsp;between higher serum&nbsp;25(OH)D concentrations&nbsp;and larger values of BMC&nbsp;indices for older children&nbsp;and adolescents</span></p></td><td><p><span class=font0>(8 RCTs) 1 RCT in infants showed a trend toward a&nbsp;positive effect on BMC; 1&nbsp;RCT in postmenopausal&nbsp;women showed reduced&nbsp;loss of hip BMD but not&nbsp;spinal; 6 RCTs showed no&nbsp;effect</span></p></td><td><p><span class=font0>None included</span></p></td><td><p><span class=font0>Both 2009 and newer studies had mixed results</span></p></td></tr><tr><td><p><span class=font0>Fracture</span></p></td><td><p><span class=font0>(3 RCTs) no effect of vitamin D on&nbsp;total fracture risk</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>Conclusions based on</span></p><p><span class=font0>2006 Ottawa EPC report were mixed</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>(8 observational studies) 3 studies of&nbsp;hip fracture showed&nbsp;mixed results; 1&nbsp;showed a significant&nbsp;inverse association.&nbsp;Two studies of&nbsp;nonvertebral fracture&nbsp;showed no&nbsp;association; 1&nbsp;showed a significant&nbsp;association.</span></p><p><span class=font0>Two studies of total fragility fracture&nbsp;showed mixed&nbsp;results.</span></p></td><td><p><span class=font0>Both 2009 and newer studies had mixed results</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font0>Muscle</span></p><p><span class=font0>strength/</span></p><p><span class=font0>falls</span></p></td><td><p><span class=font0>None included</span></p></td><td><p><span class=font0>None included</span></p></td><td><p><span class=font0>Conclusions based on 2006 Ottawa EPC report&nbsp;were mixed</span></p></td><td><p><span class=font0>(2 RCTs on fall risk in elderly) 1 reported no effect;</span></p><p><span class=font0>1 reported effects only in subgroups)</span></p><p><span class=font0>(2 RCTs on muscle strength) both showed&nbsp;positive effects but one&nbsp;showed effects only in those&nbsp;with lower serum 25(OH)D</span></p></td><td style=vertical-align:bottom><p><span class=font0>(1 prospective cohort on falls)&nbsp;inverse association&nbsp;of 25(OH)D and falls&nbsp;risk</span></p><p><span class=font0>(4 prospective cohort studies on&nbsp;muscle strength) %&nbsp;showed inverse&nbsp;association of&nbsp;25(OH)D with&nbsp;muscle strength</span></p></td><td><p><span class=font0>Both original and newer studies had mixed results</span></p></td></tr><tr><td><p><span class=font1 style=font-weight:700>Bone Health Vitamin</span></p><p><span class=font1 style=font-weight:700>D+Ca</span></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td></tr><tr><td style=vertical-align:bottom><p><span class=font0>Rickets</span></p></td><td style=vertical-align:bottom><p><span class=font0>None identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>None identified</span></p></td><td><p></p></td><td style=vertical-align:bottom><p><span class=font0>None identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>None identified</span></p></td><td><p></p></td></tr><tr><td><p><span class=font0>BMD/BMC</span></p></td><td><p><span class=font0>(3 RCTs) 1 RCT in healthy girls&nbsp;showed no&nbsp;effects on BMC;</span></p><p><span class=font0>2 RCTs in postmenopausal&nbsp;women showed&nbsp;positive effects&nbsp;on BMD</span></p></td><td><p><span class=font0>None included</span></p></td><td><p><span class=font0>Ottawa EPC report concluded that overall,&nbsp;there is good evidence&nbsp;that vitamin D+Ca&nbsp;resulted in small&nbsp;increases in BMD of the&nbsp;spine, total body, femoral&nbsp;neck, and total hip</span></p></td><td><p><span class=font0>(7 RCTs) 2 RCTs in girls and young women showed&nbsp;positive effects; 4 RCTs in&nbsp;post- menopausal women&nbsp;had mixed effects; 1 RCT in&nbsp;men showed no effects</span></p></td><td><p><span class=font0>None included</span></p></td><td><p><span class=font0>Both original and newer studies had mixed results</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font0>Fracture</span></p></td><td><p><span class=font0>(1 RCT) Vitamin D+Ca reduced&nbsp;risk of stress&nbsp;fracture among&nbsp;premenopausal&nbsp;women</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>Ottawa EPC report concluded that&nbsp;supplementation with&nbsp;vitamin D +calcium is&nbsp;effective in reducing&nbsp;fractures in&nbsp;institutionalized&nbsp;populations</span></p></td><td style=vertical-align:bottom><p><span class=font0>(1 RCT and 1 post-hoc analysis, both rated A) Post-hoc analysis of year-7 WHI&nbsp;data showed significantly&nbsp;decreased risk for hip&nbsp;fracture (but not overall&nbsp;fracture) among women&nbsp;who did not use personal&nbsp;supplements at baseline; 3-year study of&nbsp;postmenopausal women&nbsp;found no effect on fracture&nbsp;at any site</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>General agreement among original Ottawa EPC report, 2009&nbsp;report, and current report that&nbsp;vitamin D+Ca reduces risk for&nbsp;some fractures but not&nbsp;consistent across fracture types&nbsp;or populations. Post-hoc analysis&nbsp;of wHi data demonstrates need&nbsp;to consider baseline supplement&nbsp;use.</span></p></td></tr><tr><td><p><span class=font0>Muscle</span></p><p><span class=font0>strength/</span></p><p><span class=font0>falls</span></p></td><td><p><span class=font0>(1 RCT) 5-year analysis of WHI&nbsp;subsample found&nbsp;no effect on&nbsp;performance</span></p></td><td><p><span class=font0>None included</span></p></td><td><p><span class=font0>Ottawa EPC report found evidence that&nbsp;supplemental vitamin D&nbsp;reduces falls in&nbsp;postmenopausal women&nbsp;and effect for older men is&nbsp;inconsistent</span></p></td><td><p><span class=font0>(1 RCT on muscle strength/1 RCT on falls) no&nbsp;effects of vitamin D+Ca on&nbsp;muscle strength or fall risk</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>2009 report consistent with current report that vitamin D+Ca&nbsp;supplementation does not affect&nbsp;risk for falls or muscle strength&nbsp;but too few studies to draw firm&nbsp;conclusions</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font1 style=font-weight:700>Pregnancy-Related Outcomes&nbsp;Vitamin D</span></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td></tr><tr><td><p><span class=font0>Birth weight/</span></p><p><span class=font0>length</span></p><p><span class=font0>(infancy)</span></p></td><td style=vertical-align:bottom><p><span class=font0>(7 RCTs) 2 out of 7 studies (from&nbsp;same center)&nbsp;reported&nbsp;significant effect&nbsp;of supplement on&nbsp;birth weight; 5&nbsp;reported no&nbsp;effects</span></p></td><td><p><span class=font0>(2 prospective cohorts) no&nbsp;effects</span></p></td><td><p><span class=font0>Diverse populations and methodological&nbsp;approaches precluded&nbsp;conclusions</span></p></td><td><p><span class=font0>(5 RCTs) 1 out of 5 reported significant effect of&nbsp;supplement intake on birth&nbsp;weight and length;&nbsp;remaining 4: no effect</span></p></td><td><p><span class=font0>(2 prospective cohorts) half&nbsp;observed&nbsp;association of 2nd&nbsp;trimester maternal&nbsp;serum 25(OH)D with&nbsp;birth weight</span></p></td><td><p><span class=font0>Only 1 C-rated RCT observed an effect of vitamin D; compliance&nbsp;was a challenge in several RCTs</span></p></td></tr><tr><td><p><span class=font0>Small-for gestational&nbsp;age (SGA)</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>NA</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>(2 prospective cohort studies) 1&nbsp;found an inverse&nbsp;association of serum&nbsp;25(OH)D with risk&nbsp;for SgA; the other&nbsp;found a U-shaped&nbsp;association</span></p></td><td><p><span class=font0>Differences in observations between studies</span></p></td></tr><tr><td><p><span class=font0>Preterm birth</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>NA</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>(1 prospective cohort study and 1&nbsp;nested case-control)&nbsp;the prospective&nbsp;cohort observed an&nbsp;inverse association&nbsp;with risk, the nested&nbsp;case-control&nbsp;observed no&nbsp;association</span></p></td><td><p><span class=font0>Differences in observations among studies</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font0>Preeclampsia</span></p></td><td><p><span class=font0>No RCTs identified</span></p></td><td><p><span class=font0>(1 nested case-control) study observed an&nbsp;association&nbsp;between serum&nbsp;25(OH)D &lt;37.5&nbsp;nmol/L and&nbsp;increased risk for&nbsp;preeclampsia</span></p></td><td><p><span class=font0>Studies too small in number to reach&nbsp;conclusions</span></p></td><td><p><span class=font0>(2 RCTs (pooled in one article)) vitamin D&nbsp;supplementation (4000IU/d&nbsp;but not 2000IU) reduced the&nbsp;risk for preeclampsia</span></p></td><td style=vertical-align:bottom><p><span class=font0>(7 observational studies (5 nested&nbsp;case-control and 2&nbsp;prospective cohort)):&nbsp;5 of 7 studies&nbsp;observed an&nbsp;association between</span></p><p><span class=font0>serum</span></p><p><span class=font0>25(OH)D&lt;50nmol/L and increased risk&nbsp;for preeclampsia</span></p></td><td><p><span class=font0>Newer studies suggest possible effect of serum 25(OH)D&nbsp;concentration or vitamin D&nbsp;supplementation on reducing risk&nbsp;for preeclampsia</span></p></td></tr><tr><td><p><span class=font1 style=font-weight:700>Pregnancy-Related Outcomes&nbsp;Vitamin D +&nbsp;Ca</span></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td></tr><tr><td><p><span class=font0>Birth</span></p><p><span class=font0>weight/length</span></p><p><span class=font0>(infancy)</span></p></td><td style=vertical-align:bottom><p><span class=font0>(1 C-rated nonrandomized&nbsp;trial) study found&nbsp;significant effect&nbsp;of vitamin D+Ca&nbsp;supplementation&nbsp;on birth weight</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>Too few studies to assess findings</span></p></td><td><p><span class=font0>No new studies identified</span></p></td><td><p><span class=font0>No new studies identified</span></p></td><td><p><span class=font0>No studies for which to assess findings</span></p></td></tr><tr><td><p><span class=font0>SGA</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies identified</span></p></td><td><p></p></td><td><p><span class=font0>No new studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>No new studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies for which to assess findings</span></p></td></tr><tr><td><p><span class=font0>Preterm birth</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies identified</span></p></td><td><p></p></td><td><p><span class=font0>No new studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>No new studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies for which to assess findings</span></p></td></tr><tr><td><p><span class=font0>Preeclampsia</span></p></td><td style=vertical-align:bottom><p><span class=font0>(1 C-rated RCT) Study found no&nbsp;significant effect&nbsp;of combined&nbsp;vitamin D (1200&nbsp;IU/d) and&nbsp;calcium (375&nbsp;mg/d) on&nbsp;prevention of&nbsp;preeclampsia</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>Too few studies to assess findings</span></p></td><td><p><span class=font0>No new studies identified</span></p></td><td><p><span class=font0>No new studies identified</span></p></td><td><p><span class=font0>No studies for which to assess findings</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>All-Cause</span></p><p><span class=font1 style=font-weight:700>Mortality</span></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td></tr><tr><td><p><span class=font0>All-cause mortality&nbsp;Vitamin D</span></p></td><td><p><span class=font0>(1 RCT and reanalysis of&nbsp;existing SR)&nbsp;vitamin D&nbsp;supplementation&nbsp;had no</span></p><p><span class=font0>significant effect</span></p></td><td><p><span class=font0>(4 cohort studies): 3&nbsp;reported no&nbsp;association; 1&nbsp;reported a trend&nbsp;toward an&nbsp;inverse&nbsp;association</span></p></td><td><p><span class=font0>No relationship of vitamin</span></p><p><span class=font0>D with all-cause mortality</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>(25 observational studies) 7 reported&nbsp;no association; 16&nbsp;reported an inverse&nbsp;association; 2&nbsp;reported a U-shaped association</span></p></td><td><p><span class=font0>Both the 2009 and the current report suggest no relationship of&nbsp;vitamin D with all-cause mortality</span></p></td></tr><tr><td><p><span class=font0>All-cause mortality&nbsp;Vitamin D+Ca</span></p></td><td style=vertical-align:bottom><p><span class=font0>(reanalysis of existing SR)&nbsp;vitamin D+Ca&nbsp;supplementation&nbsp;had no</span></p><p><span class=font0>significant effect</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>No relationship of vitamin D+Ca and all-cause&nbsp;mortality</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>No literature on vitamin D+Ca and all-cause mortality</span></p></td></tr><tr><td><p><span class=font1 style=font-weight:700>CVD</span></p><p><span class=font1 style=font-weight:700>Vitamin D</span></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td></tr><tr><td><p><span class=font0>Hypertension</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>(2 observational studies) 2 large&nbsp;prospective&nbsp;cohort studies&nbsp;observed a&nbsp;significant&nbsp;inverse&nbsp;association of&nbsp;serum 25(OH)D&nbsp;with risk for&nbsp;hypertension</span></p></td><td><p><span class=font0>Too few studies to draw conclusions</span></p></td><td><p><span class=font0>None identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>(2 observational studies) 1 C-rated&nbsp;prospective cohort&nbsp;study observed an&nbsp;inverse association&nbsp;between serum&nbsp;25(OH)D and risk&nbsp;for hypertension; 1&nbsp;A-rated cohort study&nbsp;observed a j-shaped&nbsp;association with risk&nbsp;for hypertension</span></p></td><td><p><span class=font0>Relative agreement between</span></p><p><span class=font0>2009 report findings and current report except for observed j-shaped association between&nbsp;serum 25(OH)D and&nbsp;hypertension risk</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font0>Blood</span></p><p><span class=font0>pressure</span></p></td><td style=vertical-align:bottom><p><span class=font0>(3 RCTs) 3 trials reported no&nbsp;effect of vitamin</span></p><p><span class=font0>D on diastolic blood pressure,&nbsp;but diastolic&nbsp;pressure was&nbsp;decreased in 1&nbsp;study,</span></p><p><span class=font0>unchanged in 1, and increased in</span></p><p><span class=font0>1</span></p></td><td><p></p></td><td><p></p></td><td><p><span class=font0>(10 RCTs) 7 reported no effect, vitamin D decreased&nbsp;blood pressure in 2 studies,&nbsp;and vitamin D increased&nbsp;systolic blood pressure in 1</span></p></td><td><p><span class=font0>None included</span></p></td><td><p><span class=font0>2009 report and current report agree that effects of vitamin D&nbsp;supplementation on blood&nbsp;pressure are inconsistent, based&nbsp;on small numbers of studies</span></p></td></tr><tr><td><p><span class=font0>CVD events</span></p></td><td><p><span class=font0>(1 RCT) No effect of vitamin</span></p><p><span class=font0>D</span></p><p><span class=font0>supplementation on risk for CV&nbsp;events in elderly</span></p></td><td style=vertical-align:bottom><p><span class=font0>(4 cohort studies) 2&nbsp;studies reported&nbsp;a significant&nbsp;inverse&nbsp;association&nbsp;between serum&nbsp;25(OH)D and&nbsp;total CV events;</span></p><p><span class=font0>2 studies reported no&nbsp;associations</span></p></td><td><p><span class=font0>Mixed effects reported</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>(1 SR of prospective studies; 7 new&nbsp;studies) SR found&nbsp;significant inverse&nbsp;association of serum&nbsp;25(OH)D and CV&nbsp;events; new cohort&nbsp;studies found mixed&nbsp;effects</span></p></td><td><p><span class=font0>Associations of serum 25(OH)D with CVD events observed in&nbsp;some cohort studies but not all&nbsp;and not supported by RCTs</span></p></td></tr><tr><td><p><span class=font0>CVD mortality</span></p></td><td><p><span class=font0>(1 RCT) No effect of vitamin</span></p><p><span class=font0>D</span></p><p><span class=font0>supplementation on risk for CV&nbsp;death in elderly</span></p></td><td><p><span class=font0>None included</span></p></td><td><p><span class=font0>Too few studies to draw conclusions</span></p></td><td><p><span class=font0>None identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>(7 cohort studies, 1 nested case-control)&nbsp;Increased risk for&nbsp;cardiovascular&nbsp;death for those with&nbsp;the lowest serum&nbsp;25(OH)D&nbsp;concentrations&nbsp;compared with the&nbsp;highest</span></p></td><td><p><span class=font0>Mixed findings between 1 RCT in 2009 report and 8 observational&nbsp;studies identified for current&nbsp;report</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font1 style=font-weight:700>CVD</span></p><p><span class=font1 style=font-weight:700>Vitamin</span></p><p><span class=font1 style=font-weight:700>D+Ca</span></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td></tr><tr><td><p><span class=font0>Hypertension</span></p></td><td style=vertical-align:bottom><p><span class=font0>(1 RCT) The</span></p><p><span class=font0>WHI reported no effect of vitamin&nbsp;D+Ca</span></p><p><span class=font0>supplementation on hypertension&nbsp;risk</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>No effects reported; small number of trials</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>2009 report and current report identified no effects</span></p></td></tr><tr><td><p><span class=font0>Blood</span></p><p><span class=font0>pressure</span></p></td><td><p><span class=font0>(2 RCTs) No effect of</span></p><p><span class=font0>supplementation seen on blood&nbsp;pressure at short&nbsp;or long followup&nbsp;times</span></p></td><td><p><span class=font0>None included</span></p></td><td><p><span class=font0>No effects reported; small number of trials</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>None included</span></p></td><td><p><span class=font0>2009 report and current report identified no effects</span></p></td></tr><tr><td><p><span class=font0>CVD events</span></p></td><td style=vertical-align:bottom><p><span class=font0>(1 RCT) WHI</span></p><p><span class=font0>CaD Trial 7-year followup found&nbsp;no effect on any&nbsp;CV outcome, but&nbsp;a trend toward&nbsp;increased risk for&nbsp;a composite&nbsp;cardiovascular&nbsp;outcome with&nbsp;supplementation</span></p></td><td><p><span class=font0>None included</span></p></td><td><p><span class=font0>No significant effects of Vitamin D+Ca but trend&nbsp;toward increasing risk of&nbsp;CV events with&nbsp;supplementation</span></p></td><td><p><span class=font0>(1 post-hoc analysis of the wHi trial) no effect of study&nbsp;supplements (400IU vitamin&nbsp;D3 and 1000mg Ca) alone&nbsp;on risk for CV events at >5&nbsp;years followup</span></p></td><td><p><span class=font0>None identified</span></p></td><td><p><span class=font0>Post-hoc reanalysis of WHI CaD outcomes by use of personal&nbsp;supplements at baseline finds no&nbsp;effect of study intervention on&nbsp;risk for CVD</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font1 style=font-weight:700>Cancer Vitamin D</span></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td></tr><tr><td><p><span class=font0>Total cancer/</span></p><p><span class=font0>cancer</span></p><p><span class=font0>mortality</span></p></td><td><p><span class=font0>(2 RCTs) no effect of vitamin</span></p><p><span class=font0>D</span></p><p><span class=font0>supplementation on risk for cancer&nbsp;mortality</span></p></td><td><p><span class=font0>(1 cohort study) analysis of&nbsp;NHANES III&nbsp;found no&nbsp;association&nbsp;between</span></p><p><span class=font0>25(OH)D status and risk for&nbsp;cancer mortality</span></p></td><td><p></p></td><td><p><span class=font0>No new RCTs identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>(2 cohort studies assessed&nbsp;association with&nbsp;cancer incidence)&nbsp;no association of&nbsp;25(OH)D and total&nbsp;cancer incidence&nbsp;(10 cohort studies&nbsp;and 1 nested case-control assessed&nbsp;association with&nbsp;total cancer&nbsp;mortality) 5 cohort&nbsp;studies saw no&nbsp;association; 3&nbsp;cohorts and the&nbsp;nested case-control&nbsp;observed a trend&nbsp;toward an inverse&nbsp;association; 1&nbsp;observed a trend&nbsp;toward a positive&nbsp;association; 1&nbsp;observed a U-shaped association</span></p></td><td><p><span class=font0>Totality of studies suggest no or complicated association of&nbsp;25(OH)D status with cancer&nbsp;mortality</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font0>Prostate</span></p><p><span class=font0>cancer</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>(12 nested case-control studies) 8 studies found no&nbsp;association&nbsp;between serum&nbsp;25(OH)D&nbsp;concentrations&nbsp;and prostate&nbsp;cancer risk; 1&nbsp;study found a&nbsp;significant&nbsp;inverse&nbsp;association&nbsp;between lower&nbsp;baseline serum&nbsp;25(OH)D&nbsp;concentrations&nbsp;(&lt;30 compared&nbsp;with >55 nmol/L)&nbsp;and higher risk&nbsp;(rated C);&nbsp;another C-rated&nbsp;study observed a&nbsp;U-shaped&nbsp;association (Crated)</span></p></td><td><p><span class=font0>Observational studies only; mixed findings on&nbsp;associations</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>(7 observational studies) 4 nested&nbsp;case-control studies&nbsp;and 1 cohort found&nbsp;no association of&nbsp;serum 25(OH)D with&nbsp;risk for prostate&nbsp;cancer; 2 nested&nbsp;case-controls&nbsp;observed a trend&nbsp;toward increasing&nbsp;risk with higher&nbsp;serum 25(OH)D&nbsp;concentrations</span></p></td><td><p><span class=font0>2009 and current report find observational studies only, with&nbsp;mixed findings on associations</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font0>Breast cancer</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>(2 observational studies) 2 nested&nbsp;case-controls&nbsp;observed no&nbsp;association of&nbsp;serum 25(OH)&nbsp;status with risk&nbsp;for breast cancer&nbsp;in 7-12 years&nbsp;followup</span></p></td><td><p><span class=font0>Two observational studies suggest no association</span></p></td><td><p><span class=font0>(1 RCT on breast density) vitamin D intake greater&nbsp;than 400IU/d decreased&nbsp;mammographic density</span></p></td><td style=vertical-align:bottom><p><span class=font0>(8 observational studies) 2 cohort&nbsp;and 4 nested case-control studies&nbsp;found no&nbsp;association; 2&nbsp;nested case-control&nbsp;studies found&nbsp;increasing risk of&nbsp;breast cancer with&nbsp;decreasing 25(OH)D&nbsp;concentrations</span></p></td><td><p><span class=font0>2009 and current report find observational studies only, with&nbsp;mixed findings on associations</span></p></td></tr><tr><td><p><span class=font0>Colorectal</span></p><p><span class=font0>cancer(CRC)</span></p></td><td><p><span class=font0>(1 RCT) no effect of supplements&nbsp;over 5 years&nbsp;followup</span></p></td><td style=vertical-align:bottom><p><span class=font0>(8 observational studies) 2 nested&nbsp;case-control&nbsp;studies and 1&nbsp;cohort study&nbsp;found inverse&nbsp;associations&nbsp;between</span></p><p><span class=font0>25(OH)D concentrations&nbsp;and risk for CRC;&nbsp;5 nested case-control studies&nbsp;found no&nbsp;association</span></p></td><td><p><span class=font0>Observational studies report mixed associations&nbsp;and RCT shows no effect</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>(4 observational studies) 3 nested&nbsp;case-control studies&nbsp;identified a trend&nbsp;toward an inverse&nbsp;association of&nbsp;25(OH)D and CRC&nbsp;risk; 1 nested case-control found no&nbsp;association</span></p></td><td><p><span class=font0>2009 and current report identify mixed findings</span></p></td></tr><tr><td><p><span class=font0>Pancreatic</span></p><p><span class=font0>cancer</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>(2 observational studies) risk for&nbsp;pancreatic&nbsp;cancer increased&nbsp;with increasing&nbsp;serum 25(OH)D&nbsp;concentrations</span></p></td><td><p><span class=font0>Two few studies to draw conclusions</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>(8 nested case-controls pooled) risk for pancreatic&nbsp;cancer increased&nbsp;among those with&nbsp;25(OH)D>100&nbsp;nmol/L compared&nbsp;with &lt;25nmol/L</span></p></td><td><p><span class=font0>Observational studies in 2009 and current reports suggest&nbsp;increasing risk for pancreatic&nbsp;cancer with increasing serum&nbsp;25(OH)D</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font1 style=font-weight:700>Cancer</span></p><p><span class=font1 style=font-weight:700>Vitamin</span></p><p><span class=font1 style=font-weight:700>D+Ca</span></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td></tr><tr><td style=vertical-align:bottom><p><span class=font0>Total cancer mortality</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies identified</span></p></td><td><p></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies on which to base comparison or conclusions</span></p></td></tr><tr><td style=vertical-align:bottom><p><span class=font0>Prostate</span></p><p><span class=font0>cancer</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies identified</span></p></td><td><p></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies on which to base comparison or conclusions</span></p></td></tr><tr><td><p><span class=font0>Breast cancer</span></p></td><td><p><span class=font0>(WHI CaD Trial) WHI reported no&nbsp;significant effect&nbsp;of supplements&nbsp;on the risk for&nbsp;breast cancer</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p></p></td><td style=vertical-align:bottom><p><span class=font0>(WHI CaD post-hoc analysis) assessment of&nbsp;breast cancer risk among&nbsp;trial participants stratified by&nbsp;use of personal&nbsp;supplements at baseline&nbsp;reported a trend toward&nbsp;decreasing risk among&nbsp;women who did not use&nbsp;personal supplements</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>Too few studies to draw conclusions</span></p></td></tr><tr><td><p><span class=font0>Colorectal cancer (CRC)</span></p></td><td><p><span class=font0>(WHI CaD Trial) WHI reported no&nbsp;significant effect&nbsp;of supplements&nbsp;on the risk for&nbsp;CRC</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>Too few studies to draw conclusions about&nbsp;supplementation</span></p></td><td style=vertical-align:bottom><p><span class=font0>(WHI CaD post-hoc analysis) assessment of</span></p><p><span class=font0>CRC risk among trial participants stratified by use&nbsp;of personal supplements at&nbsp;baseline reported no&nbsp;difference in risk between&nbsp;personal supplement users&nbsp;and those who did not use&nbsp;personal supplements</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>Too few studies to draw conclusions</span></p></td></tr><tr><td><p><span class=font0>Pancreatic</span></p><p><span class=font0>cancer</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font1 style=font-weight:700>Immune Function&nbsp;Vitamin D</span></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td></tr><tr><td><p><span class=font0>Infectious</span></p><p><span class=font0>illnesses</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>(2 observational studies)</span></p><p><span class=font0>NHANES III found no&nbsp;significant&nbsp;association&nbsp;between serum&nbsp;25(OH)D&nbsp;concentrations&nbsp;and infectious&nbsp;disease mortality</span></p></td><td><p></p></td><td><p><span class=font0>(4 RCTs) 4 RCTs of infants and adults reported no&nbsp;effects</span></p></td><td style=vertical-align:bottom><p><span class=font0>(9 observational studies) 3 cohort&nbsp;studies observed an&nbsp;inverse association&nbsp;of cord blood&nbsp;25(OH)D and risk&nbsp;for infections at 3-6&nbsp;months; two cohort&nbsp;studies observed&nbsp;inverse associations&nbsp;among school-age&nbsp;children; 3 cohort&nbsp;studies of adults&nbsp;observed similar&nbsp;associations with&nbsp;various infectious&nbsp;illnesses</span></p></td><td><p><span class=font0>Number of studies in 2009 report too small to assess association&nbsp;of serum 25(OH)D with risk for&nbsp;infection; current report identified&nbsp;RCTs and observational studies,&nbsp;but no consistent effects or&nbsp;associations emerged</span></p></td></tr><tr><td><p><span class=font0>Autoimmune</span></p><p><span class=font0>disorders</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>No studies on which to base conclusions</span></p></td><td><p><span class=font0>(1 RCT) a subgroup analysis of WHI CaD&nbsp;participants found no effect&nbsp;of supplementation on risk&nbsp;for rheumatoid arthritis</span></p></td><td><p><span class=font0>(4 observational studies) 3 nested&nbsp;case-control studies&nbsp;and 1 cohort study&nbsp;reported mixed&nbsp;associations of&nbsp;serum 25(OH)D&nbsp;concentrations with&nbsp;risk for type 1&nbsp;diabetes; 1 study&nbsp;reported mixed&nbsp;associations of&nbsp;serum 25(OH)D with&nbsp;risk for multiple&nbsp;sclerosis</span></p></td><td><p><span class=font0>No studies in 2009 report on association of serum 25(OH)D&nbsp;with risk for autoimmune&nbsp;diseases; current report&nbsp;identified 1 RCT and&nbsp;observational studies, but no&nbsp;consistent effects or associations&nbsp;emerged</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font0>Asthma,</span></p><p><span class=font0>Wheeze,</span></p><p><span class=font0>Atopy</span></p></td><td><p></p></td><td style=vertical-align:bottom><p><span class=font0>(1 observational study) a cohort&nbsp;study suggested&nbsp;an association of&nbsp;maternal</span></p><p><span class=font0>25(OH)D concentration&nbsp;and increased&nbsp;risk for eczema&nbsp;in their children&nbsp;but did not&nbsp;assess children's&nbsp;serum 25(OH)D</span></p></td><td><p><span class=font0>Too few studies on which to base conclusions</span></p></td><td><p><span class=font0>(1 RCT) no effect of prenatal supplementation on&nbsp;risk for wheeze, atopy, or&nbsp;eczema</span></p></td><td><p><span class=font0>(5 observational studies) mixed&nbsp;associations seen in&nbsp;cohorts of children&nbsp;between serum&nbsp;25(OH)D status and&nbsp;risk for atopy,&nbsp;eczema, wheeze,&nbsp;and asthma</span></p></td><td><p><span class=font0>Number of studies in 2009 report too small to assess association&nbsp;of serum 25(OH)D with risk for&nbsp;asthma, atopy, or wheeze;&nbsp;current report identified 1 RCT&nbsp;and 5 observational studies, but&nbsp;no consistent effects or&nbsp;associations emerged</span></p></td></tr><tr><td><p><span class=font1 style=font-weight:700>Immune</span></p><p><span class=font1 style=font-weight:700>Function</span></p><p><span class=font1 style=font-weight:700>Vitamin</span></p><p><span class=font1 style=font-weight:700>D+Ca</span></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td></tr><tr><td><p></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p><span class=font0>No studies identified</span></p></td><td><p></p></td><td><p><span class=font0>No new studies identified</span></p></td><td><p><span class=font0>No new studies identified</span></p></td><td style=vertical-align:bottom><p><span class=font0>No studies identified in 2009 or current report on which to base&nbsp;conclusions</span></p></td></tr><tr><td><p><span class=font1 style=font-weight:700>Adverse</span></p><p><span class=font1 style=font-weight:700>events</span></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td><td><p></p></td></tr><tr><td><p><span class=font0>Nephro</span></p><p><span class=font0>lithiasis</span></p></td><td><p><span class=font0>(WHI CaD Trial)</span></p><p><span class=font0>trial reported</span></p><p><span class=font0>increased risk for</span></p><p><span class=font0>nephrolithiasis</span></p><p><span class=font0>among</span></p><p><span class=font0>supplement</span></p><p><span class=font0>users</span></p></td><td><p></p></td><td><p></p></td><td><p><span class=font0>(2 RCTs) no incidents of nephrolithiasis were&nbsp;reported in studies that&nbsp;administered 1100 and&nbsp;2000IU/d vitamin D</span></p></td><td><p></p></td><td><p><span class=font0>Observation of increased risk for nephrolithiasis in original WHI&nbsp;study; very small number of</span></p><p><span class=font0>RCTs identified for current report did not support this finding</span></p></td></tr></table><table border=1><tr><td><p><span class=font1 style=font-weight:700>Outcome</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;rCts) General&nbsp;Finding(s)</span></p></td><td style=vertical-align:bottom><p><span class=font1 style=font-weight:700>2009 Report (Number of&nbsp;Observational&nbsp;Studies)&nbsp;General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2009 Report Comments</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report</span></p><p><span class=font1 style=font-weight:700>(Number of RCTs) General Finding(s)</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report (Number of&nbsp;Observational&nbsp;studies) General&nbsp;Findings</span></p></td><td><p><span class=font1 style=font-weight:700>2014 Report Comments</span></p></td></tr><tr><td><p><span class=font0>Other</span></p><p><span class=font0>Adverse</span></p><p><span class=font0>Events</span></p></td><td><p><span class=font0>47 of 63 RCTs included no&nbsp;information on&nbsp;adverse events;&nbsp;no serious AEs&nbsp;were reported</span></p></td><td><p></p></td><td><p></p></td><td style=vertical-align:bottom><p><span class=font0>41 of 55 RCTs included no information on adverse&nbsp;events; 1 RCT reported that&nbsp;no adverse events were&nbsp;reported; of 9 studies that&nbsp;assessed hypercalcemia, 1&nbsp;RCT that administered&nbsp;1000IU vitamin D and&nbsp;1000mg Ca reported1 case</span></p></td><td><p></p></td><td><p><span class=font0>Few studies in the 2009 or the current report reported AEs;&nbsp;consistent finding of new serious&nbsp;AEs</span></p></td></tr><tr><td><p><span class=font1 style=font-weight:700>Dose-Response for Vitamin D</span></p></td><td><p><span class=font0>(26 RCTs) serum 25(OH)D&nbsp;increased with&nbsp;increasing&nbsp;dosages, but&nbsp;trajectories&nbsp;varied widely by&nbsp;age group,&nbsp;baseline serum&nbsp;25(OH)D, and&nbsp;duration</span></p></td><td><p><span class=font0>Not included</span></p></td><td><p></p></td><td><p><span class=font0>(1 systematic review and 19 RCTs of vitamin D3 with or&nbsp;without calcium) serum&nbsp;25(OH)D increased with&nbsp;increasing dosages but&nbsp;trajectories varied widely by&nbsp;age group, baseline serum&nbsp;25(OH)D, duration, and&nbsp;assay. Too few new studies&nbsp;included Ca to assess&nbsp;effect.</span></p></td><td><p><span class=font0>Not included</span></p></td><td><p><span class=font0>Observations based on new studies agree with those of 2009&nbsp;report; current report also&nbsp;stratified dose-response by&nbsp;assay type. Patterns appear to&nbsp;differ slightly but too few studies&nbsp;to ascertain.</span></p></td></tr></table><p><span class=font7 style=font-weight:700>Abbreviations: </span><span class=font7>25(OH)D = 25-hydroxyvitamin D; AEs = Adverse Events; BMD = Bone mineral density; BMC = Bone-mineral content; Ca = Calcium; CaD = Calcium/Vitamin D; CRC = Colorectal Cancer; CVD = Cardiovascular Disease; EPC = Evidence-based Practice Center; IU = International Unit; NHANES III = National Health and Nutrition&nbsp;Examination Survey; RCT = Randomized controlled trial; SGA = Small for gestational age; WHI = Women’s Health Initiative</span></p><p><span class=font8>ES-35</span></p></body></html></div><hr class=tag-separator><div class=tags><span>Tags: </span><a href=/tags/asthma.html><span class=tag>asthma</span></a>
<a href=/tags/atopic-dermatitis.html><span class=tag>atopic dermatitis</span></a>
<a href=/tags/autoimmune.html><span class=tag>autoimmune</span></a>
<a href=/tags/autoimmune-and-pregnancy.html><span class=tag>autoimmune and pregnancy</span></a>
<a href=/tags/blood-levels.html><span class=tag>blood levels</span></a>
<a href=/tags/bone.html><span class=tag>bone</span></a>
<a href=/tags/bone-cancer.html><span class=tag>bone cancer</span></a>
<a href=/tags/bone-mineral-density.html><span class=tag>bone mineral density</span></a>
<a href=/tags/bone-stress-fractures.html><span class=tag>bone stress fractures</span></a>
<a href=/tags/breast-cancer.html><span class=tag>breast cancer</span></a>
<a href=/tags/breathing.html><span class=tag>breathing</span></a>
<a href=/tags/calcium.html><span class=tag>Calcium</span></a>
<a href=/tags/cancer.html><span class=tag>cancer</span></a>
<a href=/tags/cardiovascular.html><span class=tag>cardiovascular</span></a>
<a href=/tags/child.html><span class=tag>child</span></a>
<a href=/tags/childhood-cancer.html><span class=tag>childhood cancer</span></a>
<a href=/tags/childhood-obesity.html><span class=tag>childhood obesity</span></a>
<a href=/tags/childhood-pneumonia.html><span class=tag>childhood pneumonia</span></a>
<a href=/tags/childhood-respiratory.html><span class=tag>childhood respiratory</span></a>
<a href=/tags/childhood-viruses.html><span class=tag>childhood viruses</span></a>
<a href=/tags/colon-cancer.html><span class=tag>colon cancer</span></a>
<a href=/tags/deficiency.html><span class=tag>Deficiency </span></a><a href=/tags/dermatology.html><span class=tag>dermatology</span></a>
<a href=/tags/diabetes.html><span class=tag>diabetes</span></a>
<a href=/tags/dosage.html><span class=tag>dosage</span></a>
<a href=/tags/falls-fractures.html><span class=tag>falls fractures</span></a>
<a href=/tags/health-risk.html><span class=tag>health risk</span></a>
<a href=/tags/heart-failure.html><span class=tag>heart failure</span></a>
<a href=/tags/high-dose.html><span class=tag>high dose</span></a>
<a href=/tags/hip-fractures.html><span class=tag>hip fractures</span></a>
<a href=/tags/hypertension.html><span class=tag>hypertension</span></a>
<a href=/tags/intervention.html><span class=tag>intervention</span></a>
<a href=/tags/life-span.html><span class=tag>life span</span></a>
<a href=/tags/metabolic.html><span class=tag>metabolic</span></a>
<a href=/tags/mortality.html><span class=tag>mortality</span></a>
<a href=/tags/multiple-sclerosis.html><span class=tag>multiple sclerosis</span></a>
<a href=/tags/multiple-sclerosis-and-pregnancy.html><span class=tag>multiple sclerosis and pregnancy</span></a>
<a href=/tags/obesity.html><span class=tag>obesity</span></a>
<a href=/tags/obesity-and-cancer.html><span class=tag>obesity and cancer</span></a>
<a href=/tags/pain.html><span class=tag>pain</span></a>
<a href=/tags/pancreatic-cancer.html><span class=tag>pancreatic cancer</span></a>
<a href=/tags/pediatric-autoimmune.html><span class=tag>pediatric autoimmune</span></a>
<a href=/tags/pneumonia.html><span class=tag>pneumonia</span></a>
<a href=/tags/preeclampsia.html><span class=tag>preeclampsia</span></a>
<a href=/tags/pregnancy.html><span class=tag>pregnancy</span></a>
<a href=/tags/preterm.html><span class=tag>preterm</span></a>
<a href=/tags/prostate-cancer.html><span class=tag>prostate cancer</span></a>
<a href=/tags/respiratory.html><span class=tag>respiratory</span></a>
<a href=/tags/rheumatoid-arthritis.html><span class=tag>rheumatoid arthritis</span></a>
<a href=/tags/rickets.html><span class=tag>rickets</span></a>
<a href=/tags/stroke.html><span class=tag>stroke</span></a>
<a href=/tags/therapeutic-intervention.html><span class=tag>therapeutic intervention</span></a>
<a href=/tags/type-1-diabetes.html><span class=tag>type 1 diabetes</span></a>
<a href=/tags/virus.html><span class=tag>virus</span></a>
<a href=/tags/virus-and-cardiovascular.html><span class=tag>virus and cardiovascular</span></a>
<a href=/tags/virus-and-obesity.html><span class=tag>virus and obesity</span></a>
<a href=/tags/viruses-and-pregnancy.html><span class=tag>viruses and pregnancy</span></a>
<a href=/tags/vitamin-d.html><span class=tag>vitamin d</span></a>
<a href=/tags/vitamin-d-and-viruses.html><span class=tag>vitamin d and viruses</span></a>
<a href=/tags/vitamin-d-blood-test.html><span class=tag>vitamin d blood test</span></a></div><div data-pagefind-meta=tags hidden>asthma, atopic dermatitis, autoimmune, autoimmune and pregnancy, blood levels, bone, bone cancer, bone mineral density, bone stress fractures, breast cancer, breathing, Calcium, cancer, cardiovascular, child, childhood cancer, childhood obesity, childhood pneumonia, childhood respiratory, childhood viruses, colon cancer, Deficiency , dermatology, diabetes, dosage, falls fractures, health risk, heart failure, high dose, hip fractures, hypertension, intervention, life span, metabolic, mortality, multiple sclerosis, multiple sclerosis and pregnancy, obesity, obesity and cancer, pain, pancreatic cancer, pediatric autoimmune, pneumonia, preeclampsia, pregnancy, preterm, prostate cancer, respiratory, rheumatoid arthritis, rickets, stroke, therapeutic intervention, type 1 diabetes, virus, virus and cardiovascular, virus and obesity, viruses and pregnancy, vitamin d, vitamin d and viruses, vitamin d blood test</div><div class=scroll-nav-bottom id=article-bottom><a href=javascript:void(0); id=scroll-to-top class=scroll-button aria-label="Scroll to top" onclick='return window.scrollTo({top:0,behavior:"smooth"}),!1'><svg width="16" height="16" fill="currentcolor" viewBox="0 0 16 16"><path d="M8 12a.5.5.0 00.5-.5V5.707l2.146 2.147a.5.5.0 00.708-.708l-3-3a.5.5.0 00-.708.0l-3 3a.5.5.0 10.708.708L7.5 5.707V11.5a.5.5.0 00.5.5z"/></svg>
<span>Back to Top</span></a></div></article></div></div><script src="/js/toc-sanitizer.js?v=1753298154"></script><script src="/js/tiki-redirects.js?v=1753298154"></script><script src="/js/lightspa.js?v=1753298154"></script><script>const spa=new LightSPA({mainContentSelector:'[role="main"]',navigationSelector:"[data-spa-nav]"});window.search=new Search({documentsUrl:"/search/search_documents.json.gz?v=1753298154",indexUrl:"/search/search_index.json.gz?v=1753298154"}),document.addEventListener("DOMContentLoaded",function(){function e(e){var t=e.querySelector(".category-expander"),n=e.querySelector(".subcategory-list");e.classList.contains("collapsed")?(e.classList.remove("collapsed"),e.classList.add("expanded"),t.textContent="-",n.style.display="block"):(e.classList.remove("expanded"),e.classList.add("collapsed"),t.textContent="+",n.style.display="none")}document.querySelectorAll(".category-expander").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})}),document.querySelectorAll(".category-name").forEach(function(t){t.addEventListener("click",function(t){t.stopPropagation();var n=this.closest(".top-level-category");e(n)})})})</script><script src="/js/scroll-buttons.js?v=1753298154"></script></body></html>